cohortId,targetId,targetName,strataId,strataName,cohortType
1001,1001,Hydroxychloroquine ,0,All,Target
1002,1002,Hydroxychloroquine + Azithromycin ,0,All,Target
1003,1003,Hydroxychloroquine + Fluoroquinolones,0,All,Target
1004,1004,Hydroxychloroquine + Amoxicillin,0,All,Target
1005,1005,Hydroxychloroquine + ceftriaxone,0,All,Target
1006,1006,Chloroquine,0,All,Target
1007,1007,Azithromycin,0,All,Target
1008,1008,Fluoroquinolones,0,All,Target
1009,1009,Amoxicillin,0,All,Target
1010,1010,Ceftriaxone,0,All,Target
1011,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",0,All,Target
1012,1012,tocilizumab,0,All,Target
1013,1013,siltuximab,0,All,Target
1014,1014,sarilumab,0,All,Target
1015,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",0,All,Target
1016,1016,baricitinib,0,All,Target
1017,1017,tofacitinib,0,All,Target
1018,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",0,All,Target
1019,1019,adalimumab,0,All,Target
1020,1020,etanercept,0,All,Target
1021,1021,infliximab,0,All,Target
1022,1022,ustekinumab,0,All,Target
1023,1023,Anakinra,0,All,Target
1024,1024,HIV Protease inhibitors,0,All,Target
1025,1025,ritonavir/lopinavir,0,All,Target
1026,1026,Interferon beta 1b,0,All,Target
1027,1027,Interferon beta 1a,0,All,Target
1028,1028,Interferon alfa 2a,0,All,Target
1029,1029,favipiravir,0,All,Target
1030,1030,Remdesivir,0,All,Target
1031,1031,ribavirin,0,All,Target
1032,1032,oseltamivir,0,All,Target
1033,1033,Ivermectin,0,All,Target
1034,1034,itraconazole,0,All,Target
1035,1035,warfarin,0,All,Target
1041,1041,acenocoumarol,0,All,Target
1036,1036,heparin,0,All,Target
1037,1037,enoxaparin,0,All,Target
1038,1038,edoxaban,0,All,Target
1039,1039,dabigatran,0,All,Target
1040,1040,rivaroxaban,0,All,Target
1042,1042,apixaban,0,All,Target
1043,1043,bemiparin,0,All,Target
1044,1044,clopidogrel,0,All,Target
1045,1045,aspirin,0,All,Target
1046,1046,prasugrel,0,All,Target
1047,1047,alteplase,0,All,Target
1048,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",0,All,Target
1049,1049,tranexamic acid,0,All,Target
1050,1050,Ruxolitinib,0,All,Target
1051,1051,Siltuximab,0,All,Target
1052,1052,ACE inhibitors,0,All,Target
1053,1053,Angiotensin receptor blockers (ARBs),0,All,Target
1054,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),0,All,Target
1055,1055,Thiazide or thiazide-like diuretics,0,All,Target
1056,1056,Hydrocortisone,0,All,Target
1057,1057,dexamethasone,0,All,Target
1058,1058,prednisone or prednisolone,0,All,Target
1059,1059,raloxifene,0,All,Target
1060,1060,Bevacizumab,0,All,Target
1061,1061,Fingolimod,0,All,Target
1062,1062,eculizumab ,0,All,Target
1063,1063,Statins,0,All,Target
1064,1064,metformin,0,All,Target
1065,1065,DPP-4 inhibitors,0,All,Target
1066,1066,SGLT2 inhibitors,0,All,Target
1067,1067,GLP1 inhibitors,0,All,Target
1068,1068,H2 receptor antagonist,0,All,Target
1069,1069,famotidine,0,All,Target
1070,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",0,All,Target
1071,1071,prazosin,0,All,Target
1072,1072,terazosin,0,All,Target
1073,1073,doxazosin,0,All,Target
1074,1074,tamsulosin,0,All,Target
1075,1075,BCG vaccine,0,All,Target
1076,1076,Colchicine,0,All,Target
1077,1077,Losartan,0,All,Target
1078,1078,cholecalciferol,0,All,Target
1079,1079,Ibrutinib,0,All,Target
1080,1080,abiraterone,0,All,Target
1081,1081,bicalutamide,0,All,Target
1082,1082,emtricitabine,0,All,Target
1083,1083,tacrolimus,0,All,Target
1001020012,1001,Hydroxychloroquine ,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1002020012,1002,Hydroxychloroquine + Azithromycin ,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1003020012,1003,Hydroxychloroquine + Fluoroquinolones,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1004020012,1004,Hydroxychloroquine + Amoxicillin,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1005020012,1005,Hydroxychloroquine + ceftriaxone,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1006020012,1006,Chloroquine,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1007020012,1007,Azithromycin,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1008020012,1008,Fluoroquinolones,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1009020012,1009,Amoxicillin,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1010020012,1010,Ceftriaxone,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1011020012,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1012020012,1012,tocilizumab,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1013020012,1013,siltuximab,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1014020012,1014,sarilumab,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1015020012,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1016020012,1016,baricitinib,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1017020012,1017,tofacitinib,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1018020012,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1019020012,1019,adalimumab,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1020020012,1020,etanercept,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1021020012,1021,infliximab,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1022020012,1022,ustekinumab,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1023020012,1023,Anakinra,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1024020012,1024,HIV Protease inhibitors,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1025020012,1025,ritonavir/lopinavir,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1026020012,1026,Interferon beta 1b,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1027020012,1027,Interferon beta 1a,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1028020012,1028,Interferon alfa 2a,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1029020012,1029,favipiravir,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1030020012,1030,Remdesivir,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1031020012,1031,ribavirin,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1032020012,1032,oseltamivir,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1033020012,1033,Ivermectin,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1034020012,1034,itraconazole,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1035020012,1035,warfarin,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1036020012,1036,heparin,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1037020012,1037,enoxaparin,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1038020012,1038,edoxaban,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1039020012,1039,dabigatran,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1040020012,1040,rivaroxaban,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1041020012,1041,acenocoumarol,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1042020012,1042,apixaban,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1043020012,1043,bemiparin,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1044020012,1044,clopidogrel,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1045020012,1045,aspirin,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1046020012,1046,prasugrel,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1047020012,1047,alteplase,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1048020012,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1049020012,1049,tranexamic acid,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1050020012,1050,Ruxolitinib,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1051020012,1051,Siltuximab,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1052020012,1052,ACE inhibitors,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1053020012,1053,Angiotensin receptor blockers (ARBs),2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1054020012,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1055020012,1055,Thiazide or thiazide-like diuretics,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1056020012,1056,Hydrocortisone,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1057020012,1057,dexamethasone,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1058020012,1058,prednisone or prednisolone,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1059020012,1059,raloxifene,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1060020012,1060,Bevacizumab,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1061020012,1061,Fingolimod,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1062020012,1062,eculizumab ,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1063020012,1063,Statins,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1064020012,1064,metformin,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1065020012,1065,DPP-4 inhibitors,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1066020012,1066,SGLT2 inhibitors,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1067020012,1067,GLP1 inhibitors,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1068020012,1068,H2 receptor antagonist,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1069020012,1069,famotidine,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1070020012,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1071020012,1071,prazosin,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1072020012,1072,terazosin,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1073020012,1073,doxazosin,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1074020012,1074,tamsulosin,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1075020012,1075,BCG vaccine,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1076020012,1076,Colchicine,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1077020012,1077,Losartan,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1078020012,1078,cholecalciferol,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1079020012,1079,Ibrutinib,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1080020012,1080,abiraterone,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1081020012,1081,bicalutamide,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1082020012,1082,emtricitabine,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1083020012,1083,tacrolimus,2001,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwoS
1001020022,1001,Hydroxychloroquine ,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1002020022,1002,Hydroxychloroquine + Azithromycin ,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1003020022,1003,Hydroxychloroquine + Fluoroquinolones,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1004020022,1004,Hydroxychloroquine + Amoxicillin,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1005020022,1005,Hydroxychloroquine + ceftriaxone,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1006020022,1006,Chloroquine,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1007020022,1007,Azithromycin,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1008020022,1008,Fluoroquinolones,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1009020022,1009,Amoxicillin,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1010020022,1010,Ceftriaxone,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1011020022,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1012020022,1012,tocilizumab,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1013020022,1013,siltuximab,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1014020022,1014,sarilumab,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1015020022,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1016020022,1016,baricitinib,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1017020022,1017,tofacitinib,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1018020022,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1019020022,1019,adalimumab,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1020020022,1020,etanercept,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1021020022,1021,infliximab,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1022020022,1022,ustekinumab,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1023020022,1023,Anakinra,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1024020022,1024,HIV Protease inhibitors,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1025020022,1025,ritonavir/lopinavir,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1026020022,1026,Interferon beta 1b,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1027020022,1027,Interferon beta 1a,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1028020022,1028,Interferon alfa 2a,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1029020022,1029,favipiravir,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1030020022,1030,Remdesivir,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1031020022,1031,ribavirin,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1032020022,1032,oseltamivir,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1033020022,1033,Ivermectin,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1034020022,1034,itraconazole,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1035020022,1035,warfarin,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1036020022,1036,heparin,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1037020022,1037,enoxaparin,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1038020022,1038,edoxaban,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1039020022,1039,dabigatran,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1040020022,1040,rivaroxaban,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1041020022,1041,acenocoumarol,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1042020022,1042,apixaban,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1043020022,1043,bemiparin,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1044020022,1044,clopidogrel,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1045020022,1045,aspirin,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1046020022,1046,prasugrel,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1047020022,1047,alteplase,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1048020022,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1049020022,1049,tranexamic acid,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1050020022,1050,Ruxolitinib,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1051020022,1051,Siltuximab,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1052020022,1052,ACE inhibitors,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1053020022,1053,Angiotensin receptor blockers (ARBs),2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1054020022,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1055020022,1055,Thiazide or thiazide-like diuretics,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1056020022,1056,Hydrocortisone,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1057020022,1057,dexamethasone,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1058020022,1058,prednisone or prednisolone,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1059020022,1059,raloxifene,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1060020022,1060,Bevacizumab,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1061020022,1061,Fingolimod,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1062020022,1062,eculizumab ,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1063020022,1063,Statins,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1064020022,1064,metformin,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1065020022,1065,DPP-4 inhibitors,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1066020022,1066,SGLT2 inhibitors,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1067020022,1067,GLP1 inhibitors,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1068020022,1068,H2 receptor antagonist,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1069020022,1069,famotidine,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1070020022,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1071020022,1071,prazosin,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1072020022,1072,terazosin,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1073020022,1073,doxazosin,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1074020022,1074,tamsulosin,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1075020022,1075,BCG vaccine,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1076020022,1076,Colchicine,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1077020022,1077,Losartan,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1078020022,1078,cholecalciferol,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1079020022,1079,Ibrutinib,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1080020022,1080,abiraterone,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1081020022,1081,bicalutamide,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1082020022,1082,emtricitabine,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1083020022,1083,tacrolimus,2002,without  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwoS
1001020032,1001,Hydroxychloroquine ,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1002020032,1002,Hydroxychloroquine + Azithromycin ,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1003020032,1003,Hydroxychloroquine + Fluoroquinolones,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1004020032,1004,Hydroxychloroquine + Amoxicillin,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1005020032,1005,Hydroxychloroquine + ceftriaxone,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1006020032,1006,Chloroquine,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1007020032,1007,Azithromycin,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1008020032,1008,Fluoroquinolones,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1009020032,1009,Amoxicillin,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1010020032,1010,Ceftriaxone,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1011020032,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1012020032,1012,tocilizumab,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1013020032,1013,siltuximab,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1014020032,1014,sarilumab,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1015020032,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1016020032,1016,baricitinib,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1017020032,1017,tofacitinib,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1018020032,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1019020032,1019,adalimumab,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1020020032,1020,etanercept,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1021020032,1021,infliximab,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1022020032,1022,ustekinumab,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1023020032,1023,Anakinra,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1024020032,1024,HIV Protease inhibitors,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1025020032,1025,ritonavir/lopinavir,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1026020032,1026,Interferon beta 1b,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1027020032,1027,Interferon beta 1a,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1028020032,1028,Interferon alfa 2a,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1029020032,1029,favipiravir,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1030020032,1030,Remdesivir,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1031020032,1031,ribavirin,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1032020032,1032,oseltamivir,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1033020032,1033,Ivermectin,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1034020032,1034,itraconazole,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1035020032,1035,warfarin,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1036020032,1036,heparin,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1037020032,1037,enoxaparin,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1038020032,1038,edoxaban,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1039020032,1039,dabigatran,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1040020032,1040,rivaroxaban,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1041020032,1041,acenocoumarol,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1042020032,1042,apixaban,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1043020032,1043,bemiparin,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1044020032,1044,clopidogrel,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1045020032,1045,aspirin,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1046020032,1046,prasugrel,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1047020032,1047,alteplase,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1048020032,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1049020032,1049,tranexamic acid,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1050020032,1050,Ruxolitinib,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1051020032,1051,Siltuximab,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1052020032,1052,ACE inhibitors,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1053020032,1053,Angiotensin receptor blockers (ARBs),2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1054020032,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1055020032,1055,Thiazide or thiazide-like diuretics,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1056020032,1056,Hydrocortisone,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1057020032,1057,dexamethasone,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1058020032,1058,prednisone or prednisolone,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1059020032,1059,raloxifene,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1060020032,1060,Bevacizumab,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1061020032,1061,Fingolimod,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1062020032,1062,eculizumab ,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1063020032,1063,Statins,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1064020032,1064,metformin,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1065020032,1065,DPP-4 inhibitors,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1066020032,1066,SGLT2 inhibitors,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1067020032,1067,GLP1 inhibitors,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1068020032,1068,H2 receptor antagonist,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1069020032,1069,famotidine,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1070020032,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1071020032,1071,prazosin,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1072020032,1072,terazosin,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1073020032,1073,doxazosin,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1074020032,1074,tamsulosin,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1075020032,1075,BCG vaccine,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1076020032,1076,Colchicine,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1077020032,1077,Losartan,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1078020032,1078,cholecalciferol,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1079020032,1079,Ibrutinib,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1080020032,1080,abiraterone,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1081020032,1081,bicalutamide,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1082020032,1082,emtricitabine,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1083020032,1083,tacrolimus,2003,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwoS
1001020042,1001,Hydroxychloroquine ,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1002020042,1002,Hydroxychloroquine + Azithromycin ,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1003020042,1003,Hydroxychloroquine + Fluoroquinolones,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1004020042,1004,Hydroxychloroquine + Amoxicillin,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1005020042,1005,Hydroxychloroquine + ceftriaxone,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1006020042,1006,Chloroquine,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1007020042,1007,Azithromycin,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1008020042,1008,Fluoroquinolones,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1009020042,1009,Amoxicillin,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1010020042,1010,Ceftriaxone,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1011020042,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1012020042,1012,tocilizumab,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1013020042,1013,siltuximab,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1014020042,1014,sarilumab,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1015020042,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1016020042,1016,baricitinib,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1017020042,1017,tofacitinib,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1018020042,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1019020042,1019,adalimumab,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1020020042,1020,etanercept,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1021020042,1021,infliximab,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1022020042,1022,ustekinumab,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1023020042,1023,Anakinra,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1024020042,1024,HIV Protease inhibitors,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1025020042,1025,ritonavir/lopinavir,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1026020042,1026,Interferon beta 1b,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1027020042,1027,Interferon beta 1a,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1028020042,1028,Interferon alfa 2a,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1029020042,1029,favipiravir,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1030020042,1030,Remdesivir,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1031020042,1031,ribavirin,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1032020042,1032,oseltamivir,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1033020042,1033,Ivermectin,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1034020042,1034,itraconazole,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1035020042,1035,warfarin,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1036020042,1036,heparin,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1037020042,1037,enoxaparin,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1038020042,1038,edoxaban,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1039020042,1039,dabigatran,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1040020042,1040,rivaroxaban,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1041020042,1041,acenocoumarol,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1042020042,1042,apixaban,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1043020042,1043,bemiparin,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1044020042,1044,clopidogrel,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1045020042,1045,aspirin,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1046020042,1046,prasugrel,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1047020042,1047,alteplase,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1048020042,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1049020042,1049,tranexamic acid,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1050020042,1050,Ruxolitinib,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1051020042,1051,Siltuximab,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1052020042,1052,ACE inhibitors,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1053020042,1053,Angiotensin receptor blockers (ARBs),2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1054020042,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1055020042,1055,Thiazide or thiazide-like diuretics,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1056020042,1056,Hydrocortisone,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1057020042,1057,dexamethasone,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1058020042,1058,prednisone or prednisolone,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1059020042,1059,raloxifene,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1060020042,1060,Bevacizumab,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1061020042,1061,Fingolimod,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1062020042,1062,eculizumab ,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1063020042,1063,Statins,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1064020042,1064,metformin,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1065020042,1065,DPP-4 inhibitors,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1066020042,1066,SGLT2 inhibitors,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1067020042,1067,GLP1 inhibitors,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1068020042,1068,H2 receptor antagonist,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1069020042,1069,famotidine,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1070020042,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1071020042,1071,prazosin,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1072020042,1072,terazosin,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1073020042,1073,doxazosin,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1074020042,1074,tamsulosin,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1075020042,1075,BCG vaccine,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1076020042,1076,Colchicine,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1077020042,1077,Losartan,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1078020042,1078,cholecalciferol,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1079020042,1079,Ibrutinib,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1080020042,1080,abiraterone,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1081020042,1081,bicalutamide,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1082020042,1082,emtricitabine,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1083020042,1083,tacrolimus,2004,"without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwoS
1001020052,1001,Hydroxychloroquine ,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1002020052,1002,Hydroxychloroquine + Azithromycin ,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1003020052,1003,Hydroxychloroquine + Fluoroquinolones,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1004020052,1004,Hydroxychloroquine + Amoxicillin,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1005020052,1005,Hydroxychloroquine + ceftriaxone,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1006020052,1006,Chloroquine,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1007020052,1007,Azithromycin,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1008020052,1008,Fluoroquinolones,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1009020052,1009,Amoxicillin,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1010020052,1010,Ceftriaxone,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1011020052,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1012020052,1012,tocilizumab,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1013020052,1013,siltuximab,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1014020052,1014,sarilumab,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1015020052,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1016020052,1016,baricitinib,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1017020052,1017,tofacitinib,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1018020052,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1019020052,1019,adalimumab,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1020020052,1020,etanercept,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1021020052,1021,infliximab,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1022020052,1022,ustekinumab,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1023020052,1023,Anakinra,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1024020052,1024,HIV Protease inhibitors,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1025020052,1025,ritonavir/lopinavir,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1026020052,1026,Interferon beta 1b,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1027020052,1027,Interferon beta 1a,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1028020052,1028,Interferon alfa 2a,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1029020052,1029,favipiravir,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1030020052,1030,Remdesivir,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1031020052,1031,ribavirin,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1032020052,1032,oseltamivir,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1033020052,1033,Ivermectin,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1034020052,1034,itraconazole,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1035020052,1035,warfarin,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1036020052,1036,heparin,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1037020052,1037,enoxaparin,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1038020052,1038,edoxaban,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1039020052,1039,dabigatran,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1040020052,1040,rivaroxaban,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1041020052,1041,acenocoumarol,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1042020052,1042,apixaban,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1043020052,1043,bemiparin,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1044020052,1044,clopidogrel,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1045020052,1045,aspirin,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1046020052,1046,prasugrel,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1047020052,1047,alteplase,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1048020052,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1049020052,1049,tranexamic acid,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1050020052,1050,Ruxolitinib,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1051020052,1051,Siltuximab,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1052020052,1052,ACE inhibitors,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1053020052,1053,Angiotensin receptor blockers (ARBs),2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1054020052,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1055020052,1055,Thiazide or thiazide-like diuretics,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1056020052,1056,Hydrocortisone,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1057020052,1057,dexamethasone,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1058020052,1058,prednisone or prednisolone,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1059020052,1059,raloxifene,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1060020052,1060,Bevacizumab,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1061020052,1061,Fingolimod,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1062020052,1062,eculizumab ,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1063020052,1063,Statins,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1064020052,1064,metformin,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1065020052,1065,DPP-4 inhibitors,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1066020052,1066,SGLT2 inhibitors,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1067020052,1067,GLP1 inhibitors,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1068020052,1068,H2 receptor antagonist,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1069020052,1069,famotidine,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1070020052,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1071020052,1071,prazosin,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1072020052,1072,terazosin,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1073020052,1073,doxazosin,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1074020052,1074,tamsulosin,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1075020052,1075,BCG vaccine,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1076020052,1076,Colchicine,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1077020052,1077,Losartan,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1078020052,1078,cholecalciferol,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1079020052,1079,Ibrutinib,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1080020052,1080,abiraterone,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1081020052,1081,bicalutamide,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1082020052,1082,emtricitabine,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1083020052,1083,tacrolimus,2005,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwoS
1001020062,1001,Hydroxychloroquine ,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1002020062,1002,Hydroxychloroquine + Azithromycin ,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1003020062,1003,Hydroxychloroquine + Fluoroquinolones,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1004020062,1004,Hydroxychloroquine + Amoxicillin,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1005020062,1005,Hydroxychloroquine + ceftriaxone,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1006020062,1006,Chloroquine,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1007020062,1007,Azithromycin,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1008020062,1008,Fluoroquinolones,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1009020062,1009,Amoxicillin,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1010020062,1010,Ceftriaxone,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1011020062,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1012020062,1012,tocilizumab,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1013020062,1013,siltuximab,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1014020062,1014,sarilumab,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1015020062,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1016020062,1016,baricitinib,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1017020062,1017,tofacitinib,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1018020062,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1019020062,1019,adalimumab,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1020020062,1020,etanercept,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1021020062,1021,infliximab,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1022020062,1022,ustekinumab,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1023020062,1023,Anakinra,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1024020062,1024,HIV Protease inhibitors,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1025020062,1025,ritonavir/lopinavir,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1026020062,1026,Interferon beta 1b,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1027020062,1027,Interferon beta 1a,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1028020062,1028,Interferon alfa 2a,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1029020062,1029,favipiravir,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1030020062,1030,Remdesivir,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1031020062,1031,ribavirin,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1032020062,1032,oseltamivir,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1033020062,1033,Ivermectin,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1034020062,1034,itraconazole,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1035020062,1035,warfarin,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1036020062,1036,heparin,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1037020062,1037,enoxaparin,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1038020062,1038,edoxaban,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1039020062,1039,dabigatran,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1040020062,1040,rivaroxaban,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1041020062,1041,acenocoumarol,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1042020062,1042,apixaban,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1043020062,1043,bemiparin,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1044020062,1044,clopidogrel,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1045020062,1045,aspirin,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1046020062,1046,prasugrel,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1047020062,1047,alteplase,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1048020062,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1049020062,1049,tranexamic acid,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1050020062,1050,Ruxolitinib,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1051020062,1051,Siltuximab,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1052020062,1052,ACE inhibitors,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1053020062,1053,Angiotensin receptor blockers (ARBs),2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1054020062,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1055020062,1055,Thiazide or thiazide-like diuretics,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1056020062,1056,Hydrocortisone,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1057020062,1057,dexamethasone,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1058020062,1058,prednisone or prednisolone,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1059020062,1059,raloxifene,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1060020062,1060,Bevacizumab,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1061020062,1061,Fingolimod,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1062020062,1062,eculizumab ,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1063020062,1063,Statins,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1064020062,1064,metformin,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1065020062,1065,DPP-4 inhibitors,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1066020062,1066,SGLT2 inhibitors,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1067020062,1067,GLP1 inhibitors,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1068020062,1068,H2 receptor antagonist,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1069020062,1069,famotidine,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1070020062,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1071020062,1071,prazosin,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1072020062,1072,terazosin,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1073020062,1073,doxazosin,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1074020062,1074,tamsulosin,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1075020062,1075,BCG vaccine,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1076020062,1076,Colchicine,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1077020062,1077,Losartan,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1078020062,1078,cholecalciferol,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1079020062,1079,Ibrutinib,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1080020062,1080,abiraterone,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1081020062,1081,bicalutamide,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1082020062,1082,emtricitabine,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1083020062,1083,tacrolimus,2006,without  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwoS
1001000011,1001,Hydroxychloroquine ,1,with Full 30-day follow up,TwS
1002000011,1002,Hydroxychloroquine + Azithromycin ,1,with Full 30-day follow up,TwS
1003000011,1003,Hydroxychloroquine + Fluoroquinolones,1,with Full 30-day follow up,TwS
1004000011,1004,Hydroxychloroquine + Amoxicillin,1,with Full 30-day follow up,TwS
1005000011,1005,Hydroxychloroquine + ceftriaxone,1,with Full 30-day follow up,TwS
1006000011,1006,Chloroquine,1,with Full 30-day follow up,TwS
1007000011,1007,Azithromycin,1,with Full 30-day follow up,TwS
1008000011,1008,Fluoroquinolones,1,with Full 30-day follow up,TwS
1009000011,1009,Amoxicillin,1,with Full 30-day follow up,TwS
1010000011,1010,Ceftriaxone,1,with Full 30-day follow up,TwS
1011000011,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",1,with Full 30-day follow up,TwS
1012000011,1012,tocilizumab,1,with Full 30-day follow up,TwS
1013000011,1013,siltuximab,1,with Full 30-day follow up,TwS
1014000011,1014,sarilumab,1,with Full 30-day follow up,TwS
1015000011,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",1,with Full 30-day follow up,TwS
1016000011,1016,baricitinib,1,with Full 30-day follow up,TwS
1017000011,1017,tofacitinib,1,with Full 30-day follow up,TwS
1018000011,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",1,with Full 30-day follow up,TwS
1019000011,1019,adalimumab,1,with Full 30-day follow up,TwS
1020000011,1020,etanercept,1,with Full 30-day follow up,TwS
1021000011,1021,infliximab,1,with Full 30-day follow up,TwS
1022000011,1022,ustekinumab,1,with Full 30-day follow up,TwS
1023000011,1023,Anakinra,1,with Full 30-day follow up,TwS
1024000011,1024,HIV Protease inhibitors,1,with Full 30-day follow up,TwS
1025000011,1025,ritonavir/lopinavir,1,with Full 30-day follow up,TwS
1026000011,1026,Interferon beta 1b,1,with Full 30-day follow up,TwS
1027000011,1027,Interferon beta 1a,1,with Full 30-day follow up,TwS
1028000011,1028,Interferon alfa 2a,1,with Full 30-day follow up,TwS
1029000011,1029,favipiravir,1,with Full 30-day follow up,TwS
1030000011,1030,Remdesivir,1,with Full 30-day follow up,TwS
1031000011,1031,ribavirin,1,with Full 30-day follow up,TwS
1032000011,1032,oseltamivir,1,with Full 30-day follow up,TwS
1033000011,1033,Ivermectin,1,with Full 30-day follow up,TwS
1034000011,1034,itraconazole,1,with Full 30-day follow up,TwS
1035000011,1035,warfarin,1,with Full 30-day follow up,TwS
1036000011,1036,heparin,1,with Full 30-day follow up,TwS
1037000011,1037,enoxaparin,1,with Full 30-day follow up,TwS
1038000011,1038,edoxaban,1,with Full 30-day follow up,TwS
1039000011,1039,dabigatran,1,with Full 30-day follow up,TwS
1040000011,1040,rivaroxaban,1,with Full 30-day follow up,TwS
1041000011,1041,acenocoumarol,1,with Full 30-day follow up,TwS
1042000011,1042,apixaban,1,with Full 30-day follow up,TwS
1043000011,1043,bemiparin,1,with Full 30-day follow up,TwS
1044000011,1044,clopidogrel,1,with Full 30-day follow up,TwS
1045000011,1045,aspirin,1,with Full 30-day follow up,TwS
1046000011,1046,prasugrel,1,with Full 30-day follow up,TwS
1047000011,1047,alteplase,1,with Full 30-day follow up,TwS
1048000011,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",1,with Full 30-day follow up,TwS
1049000011,1049,tranexamic acid,1,with Full 30-day follow up,TwS
1050000011,1050,Ruxolitinib,1,with Full 30-day follow up,TwS
1051000011,1051,Siltuximab,1,with Full 30-day follow up,TwS
1052000011,1052,ACE inhibitors,1,with Full 30-day follow up,TwS
1053000011,1053,Angiotensin receptor blockers (ARBs),1,with Full 30-day follow up,TwS
1054000011,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),1,with Full 30-day follow up,TwS
1055000011,1055,Thiazide or thiazide-like diuretics,1,with Full 30-day follow up,TwS
1056000011,1056,Hydrocortisone,1,with Full 30-day follow up,TwS
1057000011,1057,dexamethasone,1,with Full 30-day follow up,TwS
1058000011,1058,prednisone or prednisolone,1,with Full 30-day follow up,TwS
1059000011,1059,raloxifene,1,with Full 30-day follow up,TwS
1060000011,1060,Bevacizumab,1,with Full 30-day follow up,TwS
1061000011,1061,Fingolimod,1,with Full 30-day follow up,TwS
1062000011,1062,eculizumab ,1,with Full 30-day follow up,TwS
1063000011,1063,Statins,1,with Full 30-day follow up,TwS
1064000011,1064,metformin,1,with Full 30-day follow up,TwS
1065000011,1065,DPP-4 inhibitors,1,with Full 30-day follow up,TwS
1066000011,1066,SGLT2 inhibitors,1,with Full 30-day follow up,TwS
1067000011,1067,GLP1 inhibitors,1,with Full 30-day follow up,TwS
1068000011,1068,H2 receptor antagonist,1,with Full 30-day follow up,TwS
1069000011,1069,famotidine,1,with Full 30-day follow up,TwS
1070000011,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",1,with Full 30-day follow up,TwS
1071000011,1071,prazosin,1,with Full 30-day follow up,TwS
1072000011,1072,terazosin,1,with Full 30-day follow up,TwS
1073000011,1073,doxazosin,1,with Full 30-day follow up,TwS
1074000011,1074,tamsulosin,1,with Full 30-day follow up,TwS
1075000011,1075,BCG vaccine,1,with Full 30-day follow up,TwS
1076000011,1076,Colchicine,1,with Full 30-day follow up,TwS
1077000011,1077,Losartan,1,with Full 30-day follow up,TwS
1078000011,1078,cholecalciferol,1,with Full 30-day follow up,TwS
1079000011,1079,Ibrutinib,1,with Full 30-day follow up,TwS
1080000011,1080,abiraterone,1,with Full 30-day follow up,TwS
1081000011,1081,bicalutamide,1,with Full 30-day follow up,TwS
1082000011,1082,emtricitabine,1,with Full 30-day follow up,TwS
1083000011,1083,tacrolimus,1,with Full 30-day follow up,TwS
1001000021,1001,Hydroxychloroquine ,2,with < 30-day follow up,TwS
1002000021,1002,Hydroxychloroquine + Azithromycin ,2,with < 30-day follow up,TwS
1003000021,1003,Hydroxychloroquine + Fluoroquinolones,2,with < 30-day follow up,TwS
1004000021,1004,Hydroxychloroquine + Amoxicillin,2,with < 30-day follow up,TwS
1005000021,1005,Hydroxychloroquine + ceftriaxone,2,with < 30-day follow up,TwS
1006000021,1006,Chloroquine,2,with < 30-day follow up,TwS
1007000021,1007,Azithromycin,2,with < 30-day follow up,TwS
1008000021,1008,Fluoroquinolones,2,with < 30-day follow up,TwS
1009000021,1009,Amoxicillin,2,with < 30-day follow up,TwS
1010000021,1010,Ceftriaxone,2,with < 30-day follow up,TwS
1011000021,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",2,with < 30-day follow up,TwS
1012000021,1012,tocilizumab,2,with < 30-day follow up,TwS
1013000021,1013,siltuximab,2,with < 30-day follow up,TwS
1014000021,1014,sarilumab,2,with < 30-day follow up,TwS
1015000021,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",2,with < 30-day follow up,TwS
1016000021,1016,baricitinib,2,with < 30-day follow up,TwS
1017000021,1017,tofacitinib,2,with < 30-day follow up,TwS
1018000021,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",2,with < 30-day follow up,TwS
1019000021,1019,adalimumab,2,with < 30-day follow up,TwS
1020000021,1020,etanercept,2,with < 30-day follow up,TwS
1021000021,1021,infliximab,2,with < 30-day follow up,TwS
1022000021,1022,ustekinumab,2,with < 30-day follow up,TwS
1023000021,1023,Anakinra,2,with < 30-day follow up,TwS
1024000021,1024,HIV Protease inhibitors,2,with < 30-day follow up,TwS
1025000021,1025,ritonavir/lopinavir,2,with < 30-day follow up,TwS
1026000021,1026,Interferon beta 1b,2,with < 30-day follow up,TwS
1027000021,1027,Interferon beta 1a,2,with < 30-day follow up,TwS
1028000021,1028,Interferon alfa 2a,2,with < 30-day follow up,TwS
1029000021,1029,favipiravir,2,with < 30-day follow up,TwS
1030000021,1030,Remdesivir,2,with < 30-day follow up,TwS
1031000021,1031,ribavirin,2,with < 30-day follow up,TwS
1032000021,1032,oseltamivir,2,with < 30-day follow up,TwS
1033000021,1033,Ivermectin,2,with < 30-day follow up,TwS
1034000021,1034,itraconazole,2,with < 30-day follow up,TwS
1035000021,1035,warfarin,2,with < 30-day follow up,TwS
1036000021,1036,heparin,2,with < 30-day follow up,TwS
1037000021,1037,enoxaparin,2,with < 30-day follow up,TwS
1038000021,1038,edoxaban,2,with < 30-day follow up,TwS
1039000021,1039,dabigatran,2,with < 30-day follow up,TwS
1040000021,1040,rivaroxaban,2,with < 30-day follow up,TwS
1041000021,1041,acenocoumarol,2,with < 30-day follow up,TwS
1042000021,1042,apixaban,2,with < 30-day follow up,TwS
1043000021,1043,bemiparin,2,with < 30-day follow up,TwS
1044000021,1044,clopidogrel,2,with < 30-day follow up,TwS
1045000021,1045,aspirin,2,with < 30-day follow up,TwS
1046000021,1046,prasugrel,2,with < 30-day follow up,TwS
1047000021,1047,alteplase,2,with < 30-day follow up,TwS
1048000021,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",2,with < 30-day follow up,TwS
1049000021,1049,tranexamic acid,2,with < 30-day follow up,TwS
1050000021,1050,Ruxolitinib,2,with < 30-day follow up,TwS
1051000021,1051,Siltuximab,2,with < 30-day follow up,TwS
1052000021,1052,ACE inhibitors,2,with < 30-day follow up,TwS
1053000021,1053,Angiotensin receptor blockers (ARBs),2,with < 30-day follow up,TwS
1054000021,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),2,with < 30-day follow up,TwS
1055000021,1055,Thiazide or thiazide-like diuretics,2,with < 30-day follow up,TwS
1056000021,1056,Hydrocortisone,2,with < 30-day follow up,TwS
1057000021,1057,dexamethasone,2,with < 30-day follow up,TwS
1058000021,1058,prednisone or prednisolone,2,with < 30-day follow up,TwS
1059000021,1059,raloxifene,2,with < 30-day follow up,TwS
1060000021,1060,Bevacizumab,2,with < 30-day follow up,TwS
1061000021,1061,Fingolimod,2,with < 30-day follow up,TwS
1062000021,1062,eculizumab ,2,with < 30-day follow up,TwS
1063000021,1063,Statins,2,with < 30-day follow up,TwS
1064000021,1064,metformin,2,with < 30-day follow up,TwS
1065000021,1065,DPP-4 inhibitors,2,with < 30-day follow up,TwS
1066000021,1066,SGLT2 inhibitors,2,with < 30-day follow up,TwS
1067000021,1067,GLP1 inhibitors,2,with < 30-day follow up,TwS
1068000021,1068,H2 receptor antagonist,2,with < 30-day follow up,TwS
1069000021,1069,famotidine,2,with < 30-day follow up,TwS
1070000021,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",2,with < 30-day follow up,TwS
1071000021,1071,prazosin,2,with < 30-day follow up,TwS
1072000021,1072,terazosin,2,with < 30-day follow up,TwS
1073000021,1073,doxazosin,2,with < 30-day follow up,TwS
1074000021,1074,tamsulosin,2,with < 30-day follow up,TwS
1075000021,1075,BCG vaccine,2,with < 30-day follow up,TwS
1076000021,1076,Colchicine,2,with < 30-day follow up,TwS
1077000021,1077,Losartan,2,with < 30-day follow up,TwS
1078000021,1078,cholecalciferol,2,with < 30-day follow up,TwS
1079000021,1079,Ibrutinib,2,with < 30-day follow up,TwS
1080000021,1080,abiraterone,2,with < 30-day follow up,TwS
1081000021,1081,bicalutamide,2,with < 30-day follow up,TwS
1082000021,1082,emtricitabine,2,with < 30-day follow up,TwS
1083000021,1083,tacrolimus,2,with < 30-day follow up,TwS
1001000031,1001,Hydroxychloroquine ,3,with Sex = Female,TwS
1002000031,1002,Hydroxychloroquine + Azithromycin ,3,with Sex = Female,TwS
1003000031,1003,Hydroxychloroquine + Fluoroquinolones,3,with Sex = Female,TwS
1004000031,1004,Hydroxychloroquine + Amoxicillin,3,with Sex = Female,TwS
1005000031,1005,Hydroxychloroquine + ceftriaxone,3,with Sex = Female,TwS
1006000031,1006,Chloroquine,3,with Sex = Female,TwS
1007000031,1007,Azithromycin,3,with Sex = Female,TwS
1008000031,1008,Fluoroquinolones,3,with Sex = Female,TwS
1009000031,1009,Amoxicillin,3,with Sex = Female,TwS
1010000031,1010,Ceftriaxone,3,with Sex = Female,TwS
1011000031,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",3,with Sex = Female,TwS
1012000031,1012,tocilizumab,3,with Sex = Female,TwS
1013000031,1013,siltuximab,3,with Sex = Female,TwS
1014000031,1014,sarilumab,3,with Sex = Female,TwS
1015000031,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",3,with Sex = Female,TwS
1016000031,1016,baricitinib,3,with Sex = Female,TwS
1017000031,1017,tofacitinib,3,with Sex = Female,TwS
1018000031,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",3,with Sex = Female,TwS
1019000031,1019,adalimumab,3,with Sex = Female,TwS
1020000031,1020,etanercept,3,with Sex = Female,TwS
1021000031,1021,infliximab,3,with Sex = Female,TwS
1022000031,1022,ustekinumab,3,with Sex = Female,TwS
1023000031,1023,Anakinra,3,with Sex = Female,TwS
1024000031,1024,HIV Protease inhibitors,3,with Sex = Female,TwS
1025000031,1025,ritonavir/lopinavir,3,with Sex = Female,TwS
1026000031,1026,Interferon beta 1b,3,with Sex = Female,TwS
1027000031,1027,Interferon beta 1a,3,with Sex = Female,TwS
1028000031,1028,Interferon alfa 2a,3,with Sex = Female,TwS
1029000031,1029,favipiravir,3,with Sex = Female,TwS
1030000031,1030,Remdesivir,3,with Sex = Female,TwS
1031000031,1031,ribavirin,3,with Sex = Female,TwS
1032000031,1032,oseltamivir,3,with Sex = Female,TwS
1033000031,1033,Ivermectin,3,with Sex = Female,TwS
1034000031,1034,itraconazole,3,with Sex = Female,TwS
1035000031,1035,warfarin,3,with Sex = Female,TwS
1036000031,1036,heparin,3,with Sex = Female,TwS
1037000031,1037,enoxaparin,3,with Sex = Female,TwS
1038000031,1038,edoxaban,3,with Sex = Female,TwS
1039000031,1039,dabigatran,3,with Sex = Female,TwS
1040000031,1040,rivaroxaban,3,with Sex = Female,TwS
1041000031,1041,acenocoumarol,3,with Sex = Female,TwS
1042000031,1042,apixaban,3,with Sex = Female,TwS
1043000031,1043,bemiparin,3,with Sex = Female,TwS
1044000031,1044,clopidogrel,3,with Sex = Female,TwS
1045000031,1045,aspirin,3,with Sex = Female,TwS
1046000031,1046,prasugrel,3,with Sex = Female,TwS
1047000031,1047,alteplase,3,with Sex = Female,TwS
1048000031,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",3,with Sex = Female,TwS
1049000031,1049,tranexamic acid,3,with Sex = Female,TwS
1050000031,1050,Ruxolitinib,3,with Sex = Female,TwS
1051000031,1051,Siltuximab,3,with Sex = Female,TwS
1052000031,1052,ACE inhibitors,3,with Sex = Female,TwS
1053000031,1053,Angiotensin receptor blockers (ARBs),3,with Sex = Female,TwS
1054000031,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),3,with Sex = Female,TwS
1055000031,1055,Thiazide or thiazide-like diuretics,3,with Sex = Female,TwS
1056000031,1056,Hydrocortisone,3,with Sex = Female,TwS
1057000031,1057,dexamethasone,3,with Sex = Female,TwS
1058000031,1058,prednisone or prednisolone,3,with Sex = Female,TwS
1059000031,1059,raloxifene,3,with Sex = Female,TwS
1060000031,1060,Bevacizumab,3,with Sex = Female,TwS
1061000031,1061,Fingolimod,3,with Sex = Female,TwS
1062000031,1062,eculizumab ,3,with Sex = Female,TwS
1063000031,1063,Statins,3,with Sex = Female,TwS
1064000031,1064,metformin,3,with Sex = Female,TwS
1065000031,1065,DPP-4 inhibitors,3,with Sex = Female,TwS
1066000031,1066,SGLT2 inhibitors,3,with Sex = Female,TwS
1067000031,1067,GLP1 inhibitors,3,with Sex = Female,TwS
1068000031,1068,H2 receptor antagonist,3,with Sex = Female,TwS
1069000031,1069,famotidine,3,with Sex = Female,TwS
1070000031,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",3,with Sex = Female,TwS
1071000031,1071,prazosin,3,with Sex = Female,TwS
1072000031,1072,terazosin,3,with Sex = Female,TwS
1073000031,1073,doxazosin,3,with Sex = Female,TwS
1074000031,1074,tamsulosin,3,with Sex = Female,TwS
1075000031,1075,BCG vaccine,3,with Sex = Female,TwS
1076000031,1076,Colchicine,3,with Sex = Female,TwS
1077000031,1077,Losartan,3,with Sex = Female,TwS
1078000031,1078,cholecalciferol,3,with Sex = Female,TwS
1079000031,1079,Ibrutinib,3,with Sex = Female,TwS
1080000031,1080,abiraterone,3,with Sex = Female,TwS
1081000031,1081,bicalutamide,3,with Sex = Female,TwS
1082000031,1082,emtricitabine,3,with Sex = Female,TwS
1083000031,1083,tacrolimus,3,with Sex = Female,TwS
1001000041,1001,Hydroxychloroquine ,4,with Sex = Male,TwS
1002000041,1002,Hydroxychloroquine + Azithromycin ,4,with Sex = Male,TwS
1003000041,1003,Hydroxychloroquine + Fluoroquinolones,4,with Sex = Male,TwS
1004000041,1004,Hydroxychloroquine + Amoxicillin,4,with Sex = Male,TwS
1005000041,1005,Hydroxychloroquine + ceftriaxone,4,with Sex = Male,TwS
1006000041,1006,Chloroquine,4,with Sex = Male,TwS
1007000041,1007,Azithromycin,4,with Sex = Male,TwS
1008000041,1008,Fluoroquinolones,4,with Sex = Male,TwS
1009000041,1009,Amoxicillin,4,with Sex = Male,TwS
1010000041,1010,Ceftriaxone,4,with Sex = Male,TwS
1011000041,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",4,with Sex = Male,TwS
1012000041,1012,tocilizumab,4,with Sex = Male,TwS
1013000041,1013,siltuximab,4,with Sex = Male,TwS
1014000041,1014,sarilumab,4,with Sex = Male,TwS
1015000041,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",4,with Sex = Male,TwS
1016000041,1016,baricitinib,4,with Sex = Male,TwS
1017000041,1017,tofacitinib,4,with Sex = Male,TwS
1018000041,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",4,with Sex = Male,TwS
1019000041,1019,adalimumab,4,with Sex = Male,TwS
1020000041,1020,etanercept,4,with Sex = Male,TwS
1021000041,1021,infliximab,4,with Sex = Male,TwS
1022000041,1022,ustekinumab,4,with Sex = Male,TwS
1023000041,1023,Anakinra,4,with Sex = Male,TwS
1024000041,1024,HIV Protease inhibitors,4,with Sex = Male,TwS
1025000041,1025,ritonavir/lopinavir,4,with Sex = Male,TwS
1026000041,1026,Interferon beta 1b,4,with Sex = Male,TwS
1027000041,1027,Interferon beta 1a,4,with Sex = Male,TwS
1028000041,1028,Interferon alfa 2a,4,with Sex = Male,TwS
1029000041,1029,favipiravir,4,with Sex = Male,TwS
1030000041,1030,Remdesivir,4,with Sex = Male,TwS
1031000041,1031,ribavirin,4,with Sex = Male,TwS
1032000041,1032,oseltamivir,4,with Sex = Male,TwS
1033000041,1033,Ivermectin,4,with Sex = Male,TwS
1034000041,1034,itraconazole,4,with Sex = Male,TwS
1035000041,1035,warfarin,4,with Sex = Male,TwS
1036000041,1036,heparin,4,with Sex = Male,TwS
1037000041,1037,enoxaparin,4,with Sex = Male,TwS
1038000041,1038,edoxaban,4,with Sex = Male,TwS
1039000041,1039,dabigatran,4,with Sex = Male,TwS
1040000041,1040,rivaroxaban,4,with Sex = Male,TwS
1041000041,1041,acenocoumarol,4,with Sex = Male,TwS
1042000041,1042,apixaban,4,with Sex = Male,TwS
1043000041,1043,bemiparin,4,with Sex = Male,TwS
1044000041,1044,clopidogrel,4,with Sex = Male,TwS
1045000041,1045,aspirin,4,with Sex = Male,TwS
1046000041,1046,prasugrel,4,with Sex = Male,TwS
1047000041,1047,alteplase,4,with Sex = Male,TwS
1048000041,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",4,with Sex = Male,TwS
1049000041,1049,tranexamic acid,4,with Sex = Male,TwS
1050000041,1050,Ruxolitinib,4,with Sex = Male,TwS
1051000041,1051,Siltuximab,4,with Sex = Male,TwS
1052000041,1052,ACE inhibitors,4,with Sex = Male,TwS
1053000041,1053,Angiotensin receptor blockers (ARBs),4,with Sex = Male,TwS
1054000041,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),4,with Sex = Male,TwS
1055000041,1055,Thiazide or thiazide-like diuretics,4,with Sex = Male,TwS
1056000041,1056,Hydrocortisone,4,with Sex = Male,TwS
1057000041,1057,dexamethasone,4,with Sex = Male,TwS
1058000041,1058,prednisone or prednisolone,4,with Sex = Male,TwS
1059000041,1059,raloxifene,4,with Sex = Male,TwS
1060000041,1060,Bevacizumab,4,with Sex = Male,TwS
1061000041,1061,Fingolimod,4,with Sex = Male,TwS
1062000041,1062,eculizumab ,4,with Sex = Male,TwS
1063000041,1063,Statins,4,with Sex = Male,TwS
1064000041,1064,metformin,4,with Sex = Male,TwS
1065000041,1065,DPP-4 inhibitors,4,with Sex = Male,TwS
1066000041,1066,SGLT2 inhibitors,4,with Sex = Male,TwS
1067000041,1067,GLP1 inhibitors,4,with Sex = Male,TwS
1068000041,1068,H2 receptor antagonist,4,with Sex = Male,TwS
1069000041,1069,famotidine,4,with Sex = Male,TwS
1070000041,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",4,with Sex = Male,TwS
1071000041,1071,prazosin,4,with Sex = Male,TwS
1072000041,1072,terazosin,4,with Sex = Male,TwS
1073000041,1073,doxazosin,4,with Sex = Male,TwS
1074000041,1074,tamsulosin,4,with Sex = Male,TwS
1075000041,1075,BCG vaccine,4,with Sex = Male,TwS
1076000041,1076,Colchicine,4,with Sex = Male,TwS
1077000041,1077,Losartan,4,with Sex = Male,TwS
1078000041,1078,cholecalciferol,4,with Sex = Male,TwS
1079000041,1079,Ibrutinib,4,with Sex = Male,TwS
1080000041,1080,abiraterone,4,with Sex = Male,TwS
1081000041,1081,bicalutamide,4,with Sex = Male,TwS
1082000041,1082,emtricitabine,4,with Sex = Male,TwS
1083000041,1083,tacrolimus,4,with Sex = Male,TwS
1001000051,1001,Hydroxychloroquine ,5,with Age >= 18,TwS
1002000051,1002,Hydroxychloroquine + Azithromycin ,5,with Age >= 18,TwS
1003000051,1003,Hydroxychloroquine + Fluoroquinolones,5,with Age >= 18,TwS
1004000051,1004,Hydroxychloroquine + Amoxicillin,5,with Age >= 18,TwS
1005000051,1005,Hydroxychloroquine + ceftriaxone,5,with Age >= 18,TwS
1006000051,1006,Chloroquine,5,with Age >= 18,TwS
1007000051,1007,Azithromycin,5,with Age >= 18,TwS
1008000051,1008,Fluoroquinolones,5,with Age >= 18,TwS
1009000051,1009,Amoxicillin,5,with Age >= 18,TwS
1010000051,1010,Ceftriaxone,5,with Age >= 18,TwS
1011000051,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",5,with Age >= 18,TwS
1012000051,1012,tocilizumab,5,with Age >= 18,TwS
1013000051,1013,siltuximab,5,with Age >= 18,TwS
1014000051,1014,sarilumab,5,with Age >= 18,TwS
1015000051,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",5,with Age >= 18,TwS
1016000051,1016,baricitinib,5,with Age >= 18,TwS
1017000051,1017,tofacitinib,5,with Age >= 18,TwS
1018000051,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",5,with Age >= 18,TwS
1019000051,1019,adalimumab,5,with Age >= 18,TwS
1020000051,1020,etanercept,5,with Age >= 18,TwS
1021000051,1021,infliximab,5,with Age >= 18,TwS
1022000051,1022,ustekinumab,5,with Age >= 18,TwS
1023000051,1023,Anakinra,5,with Age >= 18,TwS
1024000051,1024,HIV Protease inhibitors,5,with Age >= 18,TwS
1025000051,1025,ritonavir/lopinavir,5,with Age >= 18,TwS
1026000051,1026,Interferon beta 1b,5,with Age >= 18,TwS
1027000051,1027,Interferon beta 1a,5,with Age >= 18,TwS
1028000051,1028,Interferon alfa 2a,5,with Age >= 18,TwS
1029000051,1029,favipiravir,5,with Age >= 18,TwS
1030000051,1030,Remdesivir,5,with Age >= 18,TwS
1031000051,1031,ribavirin,5,with Age >= 18,TwS
1032000051,1032,oseltamivir,5,with Age >= 18,TwS
1033000051,1033,Ivermectin,5,with Age >= 18,TwS
1034000051,1034,itraconazole,5,with Age >= 18,TwS
1035000051,1035,warfarin,5,with Age >= 18,TwS
1036000051,1036,heparin,5,with Age >= 18,TwS
1037000051,1037,enoxaparin,5,with Age >= 18,TwS
1038000051,1038,edoxaban,5,with Age >= 18,TwS
1039000051,1039,dabigatran,5,with Age >= 18,TwS
1040000051,1040,rivaroxaban,5,with Age >= 18,TwS
1041000051,1041,acenocoumarol,5,with Age >= 18,TwS
1042000051,1042,apixaban,5,with Age >= 18,TwS
1043000051,1043,bemiparin,5,with Age >= 18,TwS
1044000051,1044,clopidogrel,5,with Age >= 18,TwS
1045000051,1045,aspirin,5,with Age >= 18,TwS
1046000051,1046,prasugrel,5,with Age >= 18,TwS
1047000051,1047,alteplase,5,with Age >= 18,TwS
1048000051,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",5,with Age >= 18,TwS
1049000051,1049,tranexamic acid,5,with Age >= 18,TwS
1050000051,1050,Ruxolitinib,5,with Age >= 18,TwS
1051000051,1051,Siltuximab,5,with Age >= 18,TwS
1052000051,1052,ACE inhibitors,5,with Age >= 18,TwS
1053000051,1053,Angiotensin receptor blockers (ARBs),5,with Age >= 18,TwS
1054000051,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),5,with Age >= 18,TwS
1055000051,1055,Thiazide or thiazide-like diuretics,5,with Age >= 18,TwS
1056000051,1056,Hydrocortisone,5,with Age >= 18,TwS
1057000051,1057,dexamethasone,5,with Age >= 18,TwS
1058000051,1058,prednisone or prednisolone,5,with Age >= 18,TwS
1059000051,1059,raloxifene,5,with Age >= 18,TwS
1060000051,1060,Bevacizumab,5,with Age >= 18,TwS
1061000051,1061,Fingolimod,5,with Age >= 18,TwS
1062000051,1062,eculizumab ,5,with Age >= 18,TwS
1063000051,1063,Statins,5,with Age >= 18,TwS
1064000051,1064,metformin,5,with Age >= 18,TwS
1065000051,1065,DPP-4 inhibitors,5,with Age >= 18,TwS
1066000051,1066,SGLT2 inhibitors,5,with Age >= 18,TwS
1067000051,1067,GLP1 inhibitors,5,with Age >= 18,TwS
1068000051,1068,H2 receptor antagonist,5,with Age >= 18,TwS
1069000051,1069,famotidine,5,with Age >= 18,TwS
1070000051,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",5,with Age >= 18,TwS
1071000051,1071,prazosin,5,with Age >= 18,TwS
1072000051,1072,terazosin,5,with Age >= 18,TwS
1073000051,1073,doxazosin,5,with Age >= 18,TwS
1074000051,1074,tamsulosin,5,with Age >= 18,TwS
1075000051,1075,BCG vaccine,5,with Age >= 18,TwS
1076000051,1076,Colchicine,5,with Age >= 18,TwS
1077000051,1077,Losartan,5,with Age >= 18,TwS
1078000051,1078,cholecalciferol,5,with Age >= 18,TwS
1079000051,1079,Ibrutinib,5,with Age >= 18,TwS
1080000051,1080,abiraterone,5,with Age >= 18,TwS
1081000051,1081,bicalutamide,5,with Age >= 18,TwS
1082000051,1082,emtricitabine,5,with Age >= 18,TwS
1083000051,1083,tacrolimus,5,with Age >= 18,TwS
1001000061,1001,Hydroxychloroquine ,6,with Age < 18,TwS
1002000061,1002,Hydroxychloroquine + Azithromycin ,6,with Age < 18,TwS
1003000061,1003,Hydroxychloroquine + Fluoroquinolones,6,with Age < 18,TwS
1004000061,1004,Hydroxychloroquine + Amoxicillin,6,with Age < 18,TwS
1005000061,1005,Hydroxychloroquine + ceftriaxone,6,with Age < 18,TwS
1006000061,1006,Chloroquine,6,with Age < 18,TwS
1007000061,1007,Azithromycin,6,with Age < 18,TwS
1008000061,1008,Fluoroquinolones,6,with Age < 18,TwS
1009000061,1009,Amoxicillin,6,with Age < 18,TwS
1010000061,1010,Ceftriaxone,6,with Age < 18,TwS
1011000061,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",6,with Age < 18,TwS
1012000061,1012,tocilizumab,6,with Age < 18,TwS
1013000061,1013,siltuximab,6,with Age < 18,TwS
1014000061,1014,sarilumab,6,with Age < 18,TwS
1015000061,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",6,with Age < 18,TwS
1016000061,1016,baricitinib,6,with Age < 18,TwS
1017000061,1017,tofacitinib,6,with Age < 18,TwS
1018000061,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",6,with Age < 18,TwS
1019000061,1019,adalimumab,6,with Age < 18,TwS
1020000061,1020,etanercept,6,with Age < 18,TwS
1021000061,1021,infliximab,6,with Age < 18,TwS
1022000061,1022,ustekinumab,6,with Age < 18,TwS
1023000061,1023,Anakinra,6,with Age < 18,TwS
1024000061,1024,HIV Protease inhibitors,6,with Age < 18,TwS
1025000061,1025,ritonavir/lopinavir,6,with Age < 18,TwS
1026000061,1026,Interferon beta 1b,6,with Age < 18,TwS
1027000061,1027,Interferon beta 1a,6,with Age < 18,TwS
1028000061,1028,Interferon alfa 2a,6,with Age < 18,TwS
1029000061,1029,favipiravir,6,with Age < 18,TwS
1030000061,1030,Remdesivir,6,with Age < 18,TwS
1031000061,1031,ribavirin,6,with Age < 18,TwS
1032000061,1032,oseltamivir,6,with Age < 18,TwS
1033000061,1033,Ivermectin,6,with Age < 18,TwS
1034000061,1034,itraconazole,6,with Age < 18,TwS
1035000061,1035,warfarin,6,with Age < 18,TwS
1036000061,1036,heparin,6,with Age < 18,TwS
1037000061,1037,enoxaparin,6,with Age < 18,TwS
1038000061,1038,edoxaban,6,with Age < 18,TwS
1039000061,1039,dabigatran,6,with Age < 18,TwS
1040000061,1040,rivaroxaban,6,with Age < 18,TwS
1041000061,1041,acenocoumarol,6,with Age < 18,TwS
1042000061,1042,apixaban,6,with Age < 18,TwS
1043000061,1043,bemiparin,6,with Age < 18,TwS
1044000061,1044,clopidogrel,6,with Age < 18,TwS
1045000061,1045,aspirin,6,with Age < 18,TwS
1046000061,1046,prasugrel,6,with Age < 18,TwS
1047000061,1047,alteplase,6,with Age < 18,TwS
1048000061,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",6,with Age < 18,TwS
1049000061,1049,tranexamic acid,6,with Age < 18,TwS
1050000061,1050,Ruxolitinib,6,with Age < 18,TwS
1051000061,1051,Siltuximab,6,with Age < 18,TwS
1052000061,1052,ACE inhibitors,6,with Age < 18,TwS
1053000061,1053,Angiotensin receptor blockers (ARBs),6,with Age < 18,TwS
1054000061,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),6,with Age < 18,TwS
1055000061,1055,Thiazide or thiazide-like diuretics,6,with Age < 18,TwS
1056000061,1056,Hydrocortisone,6,with Age < 18,TwS
1057000061,1057,dexamethasone,6,with Age < 18,TwS
1058000061,1058,prednisone or prednisolone,6,with Age < 18,TwS
1059000061,1059,raloxifene,6,with Age < 18,TwS
1060000061,1060,Bevacizumab,6,with Age < 18,TwS
1061000061,1061,Fingolimod,6,with Age < 18,TwS
1062000061,1062,eculizumab ,6,with Age < 18,TwS
1063000061,1063,Statins,6,with Age < 18,TwS
1064000061,1064,metformin,6,with Age < 18,TwS
1065000061,1065,DPP-4 inhibitors,6,with Age < 18,TwS
1066000061,1066,SGLT2 inhibitors,6,with Age < 18,TwS
1067000061,1067,GLP1 inhibitors,6,with Age < 18,TwS
1068000061,1068,H2 receptor antagonist,6,with Age < 18,TwS
1069000061,1069,famotidine,6,with Age < 18,TwS
1070000061,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",6,with Age < 18,TwS
1071000061,1071,prazosin,6,with Age < 18,TwS
1072000061,1072,terazosin,6,with Age < 18,TwS
1073000061,1073,doxazosin,6,with Age < 18,TwS
1074000061,1074,tamsulosin,6,with Age < 18,TwS
1075000061,1075,BCG vaccine,6,with Age < 18,TwS
1076000061,1076,Colchicine,6,with Age < 18,TwS
1077000061,1077,Losartan,6,with Age < 18,TwS
1078000061,1078,cholecalciferol,6,with Age < 18,TwS
1079000061,1079,Ibrutinib,6,with Age < 18,TwS
1080000061,1080,abiraterone,6,with Age < 18,TwS
1081000061,1081,bicalutamide,6,with Age < 18,TwS
1082000061,1082,emtricitabine,6,with Age < 18,TwS
1083000061,1083,tacrolimus,6,with Age < 18,TwS
1001000071,1001,Hydroxychloroquine ,7,with Age >= 65,TwS
1002000071,1002,Hydroxychloroquine + Azithromycin ,7,with Age >= 65,TwS
1003000071,1003,Hydroxychloroquine + Fluoroquinolones,7,with Age >= 65,TwS
1004000071,1004,Hydroxychloroquine + Amoxicillin,7,with Age >= 65,TwS
1005000071,1005,Hydroxychloroquine + ceftriaxone,7,with Age >= 65,TwS
1006000071,1006,Chloroquine,7,with Age >= 65,TwS
1007000071,1007,Azithromycin,7,with Age >= 65,TwS
1008000071,1008,Fluoroquinolones,7,with Age >= 65,TwS
1009000071,1009,Amoxicillin,7,with Age >= 65,TwS
1010000071,1010,Ceftriaxone,7,with Age >= 65,TwS
1011000071,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",7,with Age >= 65,TwS
1012000071,1012,tocilizumab,7,with Age >= 65,TwS
1013000071,1013,siltuximab,7,with Age >= 65,TwS
1014000071,1014,sarilumab,7,with Age >= 65,TwS
1015000071,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",7,with Age >= 65,TwS
1016000071,1016,baricitinib,7,with Age >= 65,TwS
1017000071,1017,tofacitinib,7,with Age >= 65,TwS
1018000071,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",7,with Age >= 65,TwS
1019000071,1019,adalimumab,7,with Age >= 65,TwS
1020000071,1020,etanercept,7,with Age >= 65,TwS
1021000071,1021,infliximab,7,with Age >= 65,TwS
1022000071,1022,ustekinumab,7,with Age >= 65,TwS
1023000071,1023,Anakinra,7,with Age >= 65,TwS
1024000071,1024,HIV Protease inhibitors,7,with Age >= 65,TwS
1025000071,1025,ritonavir/lopinavir,7,with Age >= 65,TwS
1026000071,1026,Interferon beta 1b,7,with Age >= 65,TwS
1027000071,1027,Interferon beta 1a,7,with Age >= 65,TwS
1028000071,1028,Interferon alfa 2a,7,with Age >= 65,TwS
1029000071,1029,favipiravir,7,with Age >= 65,TwS
1030000071,1030,Remdesivir,7,with Age >= 65,TwS
1031000071,1031,ribavirin,7,with Age >= 65,TwS
1032000071,1032,oseltamivir,7,with Age >= 65,TwS
1033000071,1033,Ivermectin,7,with Age >= 65,TwS
1034000071,1034,itraconazole,7,with Age >= 65,TwS
1035000071,1035,warfarin,7,with Age >= 65,TwS
1036000071,1036,heparin,7,with Age >= 65,TwS
1037000071,1037,enoxaparin,7,with Age >= 65,TwS
1038000071,1038,edoxaban,7,with Age >= 65,TwS
1039000071,1039,dabigatran,7,with Age >= 65,TwS
1040000071,1040,rivaroxaban,7,with Age >= 65,TwS
1041000071,1041,acenocoumarol,7,with Age >= 65,TwS
1042000071,1042,apixaban,7,with Age >= 65,TwS
1043000071,1043,bemiparin,7,with Age >= 65,TwS
1044000071,1044,clopidogrel,7,with Age >= 65,TwS
1045000071,1045,aspirin,7,with Age >= 65,TwS
1046000071,1046,prasugrel,7,with Age >= 65,TwS
1047000071,1047,alteplase,7,with Age >= 65,TwS
1048000071,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",7,with Age >= 65,TwS
1049000071,1049,tranexamic acid,7,with Age >= 65,TwS
1050000071,1050,Ruxolitinib,7,with Age >= 65,TwS
1051000071,1051,Siltuximab,7,with Age >= 65,TwS
1052000071,1052,ACE inhibitors,7,with Age >= 65,TwS
1053000071,1053,Angiotensin receptor blockers (ARBs),7,with Age >= 65,TwS
1054000071,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),7,with Age >= 65,TwS
1055000071,1055,Thiazide or thiazide-like diuretics,7,with Age >= 65,TwS
1056000071,1056,Hydrocortisone,7,with Age >= 65,TwS
1057000071,1057,dexamethasone,7,with Age >= 65,TwS
1058000071,1058,prednisone or prednisolone,7,with Age >= 65,TwS
1059000071,1059,raloxifene,7,with Age >= 65,TwS
1060000071,1060,Bevacizumab,7,with Age >= 65,TwS
1061000071,1061,Fingolimod,7,with Age >= 65,TwS
1062000071,1062,eculizumab ,7,with Age >= 65,TwS
1063000071,1063,Statins,7,with Age >= 65,TwS
1064000071,1064,metformin,7,with Age >= 65,TwS
1065000071,1065,DPP-4 inhibitors,7,with Age >= 65,TwS
1066000071,1066,SGLT2 inhibitors,7,with Age >= 65,TwS
1067000071,1067,GLP1 inhibitors,7,with Age >= 65,TwS
1068000071,1068,H2 receptor antagonist,7,with Age >= 65,TwS
1069000071,1069,famotidine,7,with Age >= 65,TwS
1070000071,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",7,with Age >= 65,TwS
1071000071,1071,prazosin,7,with Age >= 65,TwS
1072000071,1072,terazosin,7,with Age >= 65,TwS
1073000071,1073,doxazosin,7,with Age >= 65,TwS
1074000071,1074,tamsulosin,7,with Age >= 65,TwS
1075000071,1075,BCG vaccine,7,with Age >= 65,TwS
1076000071,1076,Colchicine,7,with Age >= 65,TwS
1077000071,1077,Losartan,7,with Age >= 65,TwS
1078000071,1078,cholecalciferol,7,with Age >= 65,TwS
1079000071,1079,Ibrutinib,7,with Age >= 65,TwS
1080000071,1080,abiraterone,7,with Age >= 65,TwS
1081000071,1081,bicalutamide,7,with Age >= 65,TwS
1082000071,1082,emtricitabine,7,with Age >= 65,TwS
1083000071,1083,tacrolimus,7,with Age >= 65,TwS
1001000081,1001,Hydroxychloroquine ,8,with Age < 65,TwS
1002000081,1002,Hydroxychloroquine + Azithromycin ,8,with Age < 65,TwS
1003000081,1003,Hydroxychloroquine + Fluoroquinolones,8,with Age < 65,TwS
1004000081,1004,Hydroxychloroquine + Amoxicillin,8,with Age < 65,TwS
1005000081,1005,Hydroxychloroquine + ceftriaxone,8,with Age < 65,TwS
1006000081,1006,Chloroquine,8,with Age < 65,TwS
1007000081,1007,Azithromycin,8,with Age < 65,TwS
1008000081,1008,Fluoroquinolones,8,with Age < 65,TwS
1009000081,1009,Amoxicillin,8,with Age < 65,TwS
1010000081,1010,Ceftriaxone,8,with Age < 65,TwS
1011000081,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",8,with Age < 65,TwS
1012000081,1012,tocilizumab,8,with Age < 65,TwS
1013000081,1013,siltuximab,8,with Age < 65,TwS
1014000081,1014,sarilumab,8,with Age < 65,TwS
1015000081,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",8,with Age < 65,TwS
1016000081,1016,baricitinib,8,with Age < 65,TwS
1017000081,1017,tofacitinib,8,with Age < 65,TwS
1018000081,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",8,with Age < 65,TwS
1019000081,1019,adalimumab,8,with Age < 65,TwS
1020000081,1020,etanercept,8,with Age < 65,TwS
1021000081,1021,infliximab,8,with Age < 65,TwS
1022000081,1022,ustekinumab,8,with Age < 65,TwS
1023000081,1023,Anakinra,8,with Age < 65,TwS
1024000081,1024,HIV Protease inhibitors,8,with Age < 65,TwS
1025000081,1025,ritonavir/lopinavir,8,with Age < 65,TwS
1026000081,1026,Interferon beta 1b,8,with Age < 65,TwS
1027000081,1027,Interferon beta 1a,8,with Age < 65,TwS
1028000081,1028,Interferon alfa 2a,8,with Age < 65,TwS
1029000081,1029,favipiravir,8,with Age < 65,TwS
1030000081,1030,Remdesivir,8,with Age < 65,TwS
1031000081,1031,ribavirin,8,with Age < 65,TwS
1032000081,1032,oseltamivir,8,with Age < 65,TwS
1033000081,1033,Ivermectin,8,with Age < 65,TwS
1034000081,1034,itraconazole,8,with Age < 65,TwS
1035000081,1035,warfarin,8,with Age < 65,TwS
1036000081,1036,heparin,8,with Age < 65,TwS
1037000081,1037,enoxaparin,8,with Age < 65,TwS
1038000081,1038,edoxaban,8,with Age < 65,TwS
1039000081,1039,dabigatran,8,with Age < 65,TwS
1040000081,1040,rivaroxaban,8,with Age < 65,TwS
1041000081,1041,acenocoumarol,8,with Age < 65,TwS
1042000081,1042,apixaban,8,with Age < 65,TwS
1043000081,1043,bemiparin,8,with Age < 65,TwS
1044000081,1044,clopidogrel,8,with Age < 65,TwS
1045000081,1045,aspirin,8,with Age < 65,TwS
1046000081,1046,prasugrel,8,with Age < 65,TwS
1047000081,1047,alteplase,8,with Age < 65,TwS
1048000081,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",8,with Age < 65,TwS
1049000081,1049,tranexamic acid,8,with Age < 65,TwS
1050000081,1050,Ruxolitinib,8,with Age < 65,TwS
1051000081,1051,Siltuximab,8,with Age < 65,TwS
1052000081,1052,ACE inhibitors,8,with Age < 65,TwS
1053000081,1053,Angiotensin receptor blockers (ARBs),8,with Age < 65,TwS
1054000081,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),8,with Age < 65,TwS
1055000081,1055,Thiazide or thiazide-like diuretics,8,with Age < 65,TwS
1056000081,1056,Hydrocortisone,8,with Age < 65,TwS
1057000081,1057,dexamethasone,8,with Age < 65,TwS
1058000081,1058,prednisone or prednisolone,8,with Age < 65,TwS
1059000081,1059,raloxifene,8,with Age < 65,TwS
1060000081,1060,Bevacizumab,8,with Age < 65,TwS
1061000081,1061,Fingolimod,8,with Age < 65,TwS
1062000081,1062,eculizumab ,8,with Age < 65,TwS
1063000081,1063,Statins,8,with Age < 65,TwS
1064000081,1064,metformin,8,with Age < 65,TwS
1065000081,1065,DPP-4 inhibitors,8,with Age < 65,TwS
1066000081,1066,SGLT2 inhibitors,8,with Age < 65,TwS
1067000081,1067,GLP1 inhibitors,8,with Age < 65,TwS
1068000081,1068,H2 receptor antagonist,8,with Age < 65,TwS
1069000081,1069,famotidine,8,with Age < 65,TwS
1070000081,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",8,with Age < 65,TwS
1071000081,1071,prazosin,8,with Age < 65,TwS
1072000081,1072,terazosin,8,with Age < 65,TwS
1073000081,1073,doxazosin,8,with Age < 65,TwS
1074000081,1074,tamsulosin,8,with Age < 65,TwS
1075000081,1075,BCG vaccine,8,with Age < 65,TwS
1076000081,1076,Colchicine,8,with Age < 65,TwS
1077000081,1077,Losartan,8,with Age < 65,TwS
1078000081,1078,cholecalciferol,8,with Age < 65,TwS
1079000081,1079,Ibrutinib,8,with Age < 65,TwS
1080000081,1080,abiraterone,8,with Age < 65,TwS
1081000081,1081,bicalutamide,8,with Age < 65,TwS
1082000081,1082,emtricitabine,8,with Age < 65,TwS
1083000081,1083,tacrolimus,8,with Age < 65,TwS
1001000091,1001,Hydroxychloroquine ,9,with Black or African American,TwS
1002000091,1002,Hydroxychloroquine + Azithromycin ,9,with Black or African American,TwS
1003000091,1003,Hydroxychloroquine + Fluoroquinolones,9,with Black or African American,TwS
1004000091,1004,Hydroxychloroquine + Amoxicillin,9,with Black or African American,TwS
1005000091,1005,Hydroxychloroquine + ceftriaxone,9,with Black or African American,TwS
1006000091,1006,Chloroquine,9,with Black or African American,TwS
1007000091,1007,Azithromycin,9,with Black or African American,TwS
1008000091,1008,Fluoroquinolones,9,with Black or African American,TwS
1009000091,1009,Amoxicillin,9,with Black or African American,TwS
1010000091,1010,Ceftriaxone,9,with Black or African American,TwS
1011000091,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",9,with Black or African American,TwS
1012000091,1012,tocilizumab,9,with Black or African American,TwS
1013000091,1013,siltuximab,9,with Black or African American,TwS
1014000091,1014,sarilumab,9,with Black or African American,TwS
1015000091,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",9,with Black or African American,TwS
1016000091,1016,baricitinib,9,with Black or African American,TwS
1017000091,1017,tofacitinib,9,with Black or African American,TwS
1018000091,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",9,with Black or African American,TwS
1019000091,1019,adalimumab,9,with Black or African American,TwS
1020000091,1020,etanercept,9,with Black or African American,TwS
1021000091,1021,infliximab,9,with Black or African American,TwS
1022000091,1022,ustekinumab,9,with Black or African American,TwS
1023000091,1023,Anakinra,9,with Black or African American,TwS
1024000091,1024,HIV Protease inhibitors,9,with Black or African American,TwS
1025000091,1025,ritonavir/lopinavir,9,with Black or African American,TwS
1026000091,1026,Interferon beta 1b,9,with Black or African American,TwS
1027000091,1027,Interferon beta 1a,9,with Black or African American,TwS
1028000091,1028,Interferon alfa 2a,9,with Black or African American,TwS
1029000091,1029,favipiravir,9,with Black or African American,TwS
1030000091,1030,Remdesivir,9,with Black or African American,TwS
1031000091,1031,ribavirin,9,with Black or African American,TwS
1032000091,1032,oseltamivir,9,with Black or African American,TwS
1033000091,1033,Ivermectin,9,with Black or African American,TwS
1034000091,1034,itraconazole,9,with Black or African American,TwS
1035000091,1035,warfarin,9,with Black or African American,TwS
1036000091,1036,heparin,9,with Black or African American,TwS
1037000091,1037,enoxaparin,9,with Black or African American,TwS
1038000091,1038,edoxaban,9,with Black or African American,TwS
1039000091,1039,dabigatran,9,with Black or African American,TwS
1040000091,1040,rivaroxaban,9,with Black or African American,TwS
1041000091,1041,acenocoumarol,9,with Black or African American,TwS
1042000091,1042,apixaban,9,with Black or African American,TwS
1043000091,1043,bemiparin,9,with Black or African American,TwS
1044000091,1044,clopidogrel,9,with Black or African American,TwS
1045000091,1045,aspirin,9,with Black or African American,TwS
1046000091,1046,prasugrel,9,with Black or African American,TwS
1047000091,1047,alteplase,9,with Black or African American,TwS
1048000091,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",9,with Black or African American,TwS
1049000091,1049,tranexamic acid,9,with Black or African American,TwS
1050000091,1050,Ruxolitinib,9,with Black or African American,TwS
1051000091,1051,Siltuximab,9,with Black or African American,TwS
1052000091,1052,ACE inhibitors,9,with Black or African American,TwS
1053000091,1053,Angiotensin receptor blockers (ARBs),9,with Black or African American,TwS
1054000091,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),9,with Black or African American,TwS
1055000091,1055,Thiazide or thiazide-like diuretics,9,with Black or African American,TwS
1056000091,1056,Hydrocortisone,9,with Black or African American,TwS
1057000091,1057,dexamethasone,9,with Black or African American,TwS
1058000091,1058,prednisone or prednisolone,9,with Black or African American,TwS
1059000091,1059,raloxifene,9,with Black or African American,TwS
1060000091,1060,Bevacizumab,9,with Black or African American,TwS
1061000091,1061,Fingolimod,9,with Black or African American,TwS
1062000091,1062,eculizumab ,9,with Black or African American,TwS
1063000091,1063,Statins,9,with Black or African American,TwS
1064000091,1064,metformin,9,with Black or African American,TwS
1065000091,1065,DPP-4 inhibitors,9,with Black or African American,TwS
1066000091,1066,SGLT2 inhibitors,9,with Black or African American,TwS
1067000091,1067,GLP1 inhibitors,9,with Black or African American,TwS
1068000091,1068,H2 receptor antagonist,9,with Black or African American,TwS
1069000091,1069,famotidine,9,with Black or African American,TwS
1070000091,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",9,with Black or African American,TwS
1071000091,1071,prazosin,9,with Black or African American,TwS
1072000091,1072,terazosin,9,with Black or African American,TwS
1073000091,1073,doxazosin,9,with Black or African American,TwS
1074000091,1074,tamsulosin,9,with Black or African American,TwS
1075000091,1075,BCG vaccine,9,with Black or African American,TwS
1076000091,1076,Colchicine,9,with Black or African American,TwS
1077000091,1077,Losartan,9,with Black or African American,TwS
1078000091,1078,cholecalciferol,9,with Black or African American,TwS
1079000091,1079,Ibrutinib,9,with Black or African American,TwS
1080000091,1080,abiraterone,9,with Black or African American,TwS
1081000091,1081,bicalutamide,9,with Black or African American,TwS
1082000091,1082,emtricitabine,9,with Black or African American,TwS
1083000091,1083,tacrolimus,9,with Black or African American,TwS
1001000101,1001,Hydroxychloroquine ,10,with White,TwS
1002000101,1002,Hydroxychloroquine + Azithromycin ,10,with White,TwS
1003000101,1003,Hydroxychloroquine + Fluoroquinolones,10,with White,TwS
1004000101,1004,Hydroxychloroquine + Amoxicillin,10,with White,TwS
1005000101,1005,Hydroxychloroquine + ceftriaxone,10,with White,TwS
1006000101,1006,Chloroquine,10,with White,TwS
1007000101,1007,Azithromycin,10,with White,TwS
1008000101,1008,Fluoroquinolones,10,with White,TwS
1009000101,1009,Amoxicillin,10,with White,TwS
1010000101,1010,Ceftriaxone,10,with White,TwS
1011000101,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",10,with White,TwS
1012000101,1012,tocilizumab,10,with White,TwS
1013000101,1013,siltuximab,10,with White,TwS
1014000101,1014,sarilumab,10,with White,TwS
1015000101,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",10,with White,TwS
1016000101,1016,baricitinib,10,with White,TwS
1017000101,1017,tofacitinib,10,with White,TwS
1018000101,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",10,with White,TwS
1019000101,1019,adalimumab,10,with White,TwS
1020000101,1020,etanercept,10,with White,TwS
1021000101,1021,infliximab,10,with White,TwS
1022000101,1022,ustekinumab,10,with White,TwS
1023000101,1023,Anakinra,10,with White,TwS
1024000101,1024,HIV Protease inhibitors,10,with White,TwS
1025000101,1025,ritonavir/lopinavir,10,with White,TwS
1026000101,1026,Interferon beta 1b,10,with White,TwS
1027000101,1027,Interferon beta 1a,10,with White,TwS
1028000101,1028,Interferon alfa 2a,10,with White,TwS
1029000101,1029,favipiravir,10,with White,TwS
1030000101,1030,Remdesivir,10,with White,TwS
1031000101,1031,ribavirin,10,with White,TwS
1032000101,1032,oseltamivir,10,with White,TwS
1033000101,1033,Ivermectin,10,with White,TwS
1034000101,1034,itraconazole,10,with White,TwS
1035000101,1035,warfarin,10,with White,TwS
1036000101,1036,heparin,10,with White,TwS
1037000101,1037,enoxaparin,10,with White,TwS
1038000101,1038,edoxaban,10,with White,TwS
1039000101,1039,dabigatran,10,with White,TwS
1040000101,1040,rivaroxaban,10,with White,TwS
1041000101,1041,acenocoumarol,10,with White,TwS
1042000101,1042,apixaban,10,with White,TwS
1043000101,1043,bemiparin,10,with White,TwS
1044000101,1044,clopidogrel,10,with White,TwS
1045000101,1045,aspirin,10,with White,TwS
1046000101,1046,prasugrel,10,with White,TwS
1047000101,1047,alteplase,10,with White,TwS
1048000101,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",10,with White,TwS
1049000101,1049,tranexamic acid,10,with White,TwS
1050000101,1050,Ruxolitinib,10,with White,TwS
1051000101,1051,Siltuximab,10,with White,TwS
1052000101,1052,ACE inhibitors,10,with White,TwS
1053000101,1053,Angiotensin receptor blockers (ARBs),10,with White,TwS
1054000101,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),10,with White,TwS
1055000101,1055,Thiazide or thiazide-like diuretics,10,with White,TwS
1056000101,1056,Hydrocortisone,10,with White,TwS
1057000101,1057,dexamethasone,10,with White,TwS
1058000101,1058,prednisone or prednisolone,10,with White,TwS
1059000101,1059,raloxifene,10,with White,TwS
1060000101,1060,Bevacizumab,10,with White,TwS
1061000101,1061,Fingolimod,10,with White,TwS
1062000101,1062,eculizumab ,10,with White,TwS
1063000101,1063,Statins,10,with White,TwS
1064000101,1064,metformin,10,with White,TwS
1065000101,1065,DPP-4 inhibitors,10,with White,TwS
1066000101,1066,SGLT2 inhibitors,10,with White,TwS
1067000101,1067,GLP1 inhibitors,10,with White,TwS
1068000101,1068,H2 receptor antagonist,10,with White,TwS
1069000101,1069,famotidine,10,with White,TwS
1070000101,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",10,with White,TwS
1071000101,1071,prazosin,10,with White,TwS
1072000101,1072,terazosin,10,with White,TwS
1073000101,1073,doxazosin,10,with White,TwS
1074000101,1074,tamsulosin,10,with White,TwS
1075000101,1075,BCG vaccine,10,with White,TwS
1076000101,1076,Colchicine,10,with White,TwS
1077000101,1077,Losartan,10,with White,TwS
1078000101,1078,cholecalciferol,10,with White,TwS
1079000101,1079,Ibrutinib,10,with White,TwS
1080000101,1080,abiraterone,10,with White,TwS
1081000101,1081,bicalutamide,10,with White,TwS
1082000101,1082,emtricitabine,10,with White,TwS
1083000101,1083,tacrolimus,10,with White,TwS
1001000111,1001,Hydroxychloroquine ,11,with Index date: Jan 2020,TwS
1002000111,1002,Hydroxychloroquine + Azithromycin ,11,with Index date: Jan 2020,TwS
1003000111,1003,Hydroxychloroquine + Fluoroquinolones,11,with Index date: Jan 2020,TwS
1004000111,1004,Hydroxychloroquine + Amoxicillin,11,with Index date: Jan 2020,TwS
1005000111,1005,Hydroxychloroquine + ceftriaxone,11,with Index date: Jan 2020,TwS
1006000111,1006,Chloroquine,11,with Index date: Jan 2020,TwS
1007000111,1007,Azithromycin,11,with Index date: Jan 2020,TwS
1008000111,1008,Fluoroquinolones,11,with Index date: Jan 2020,TwS
1009000111,1009,Amoxicillin,11,with Index date: Jan 2020,TwS
1010000111,1010,Ceftriaxone,11,with Index date: Jan 2020,TwS
1011000111,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",11,with Index date: Jan 2020,TwS
1012000111,1012,tocilizumab,11,with Index date: Jan 2020,TwS
1013000111,1013,siltuximab,11,with Index date: Jan 2020,TwS
1014000111,1014,sarilumab,11,with Index date: Jan 2020,TwS
1015000111,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",11,with Index date: Jan 2020,TwS
1016000111,1016,baricitinib,11,with Index date: Jan 2020,TwS
1017000111,1017,tofacitinib,11,with Index date: Jan 2020,TwS
1018000111,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",11,with Index date: Jan 2020,TwS
1019000111,1019,adalimumab,11,with Index date: Jan 2020,TwS
1020000111,1020,etanercept,11,with Index date: Jan 2020,TwS
1021000111,1021,infliximab,11,with Index date: Jan 2020,TwS
1022000111,1022,ustekinumab,11,with Index date: Jan 2020,TwS
1023000111,1023,Anakinra,11,with Index date: Jan 2020,TwS
1024000111,1024,HIV Protease inhibitors,11,with Index date: Jan 2020,TwS
1025000111,1025,ritonavir/lopinavir,11,with Index date: Jan 2020,TwS
1026000111,1026,Interferon beta 1b,11,with Index date: Jan 2020,TwS
1027000111,1027,Interferon beta 1a,11,with Index date: Jan 2020,TwS
1028000111,1028,Interferon alfa 2a,11,with Index date: Jan 2020,TwS
1029000111,1029,favipiravir,11,with Index date: Jan 2020,TwS
1030000111,1030,Remdesivir,11,with Index date: Jan 2020,TwS
1031000111,1031,ribavirin,11,with Index date: Jan 2020,TwS
1032000111,1032,oseltamivir,11,with Index date: Jan 2020,TwS
1033000111,1033,Ivermectin,11,with Index date: Jan 2020,TwS
1034000111,1034,itraconazole,11,with Index date: Jan 2020,TwS
1035000111,1035,warfarin,11,with Index date: Jan 2020,TwS
1036000111,1036,heparin,11,with Index date: Jan 2020,TwS
1037000111,1037,enoxaparin,11,with Index date: Jan 2020,TwS
1038000111,1038,edoxaban,11,with Index date: Jan 2020,TwS
1039000111,1039,dabigatran,11,with Index date: Jan 2020,TwS
1040000111,1040,rivaroxaban,11,with Index date: Jan 2020,TwS
1041000111,1041,acenocoumarol,11,with Index date: Jan 2020,TwS
1042000111,1042,apixaban,11,with Index date: Jan 2020,TwS
1043000111,1043,bemiparin,11,with Index date: Jan 2020,TwS
1044000111,1044,clopidogrel,11,with Index date: Jan 2020,TwS
1045000111,1045,aspirin,11,with Index date: Jan 2020,TwS
1046000111,1046,prasugrel,11,with Index date: Jan 2020,TwS
1047000111,1047,alteplase,11,with Index date: Jan 2020,TwS
1048000111,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",11,with Index date: Jan 2020,TwS
1049000111,1049,tranexamic acid,11,with Index date: Jan 2020,TwS
1050000111,1050,Ruxolitinib,11,with Index date: Jan 2020,TwS
1051000111,1051,Siltuximab,11,with Index date: Jan 2020,TwS
1052000111,1052,ACE inhibitors,11,with Index date: Jan 2020,TwS
1053000111,1053,Angiotensin receptor blockers (ARBs),11,with Index date: Jan 2020,TwS
1054000111,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),11,with Index date: Jan 2020,TwS
1055000111,1055,Thiazide or thiazide-like diuretics,11,with Index date: Jan 2020,TwS
1056000111,1056,Hydrocortisone,11,with Index date: Jan 2020,TwS
1057000111,1057,dexamethasone,11,with Index date: Jan 2020,TwS
1058000111,1058,prednisone or prednisolone,11,with Index date: Jan 2020,TwS
1059000111,1059,raloxifene,11,with Index date: Jan 2020,TwS
1060000111,1060,Bevacizumab,11,with Index date: Jan 2020,TwS
1061000111,1061,Fingolimod,11,with Index date: Jan 2020,TwS
1062000111,1062,eculizumab ,11,with Index date: Jan 2020,TwS
1063000111,1063,Statins,11,with Index date: Jan 2020,TwS
1064000111,1064,metformin,11,with Index date: Jan 2020,TwS
1065000111,1065,DPP-4 inhibitors,11,with Index date: Jan 2020,TwS
1066000111,1066,SGLT2 inhibitors,11,with Index date: Jan 2020,TwS
1067000111,1067,GLP1 inhibitors,11,with Index date: Jan 2020,TwS
1068000111,1068,H2 receptor antagonist,11,with Index date: Jan 2020,TwS
1069000111,1069,famotidine,11,with Index date: Jan 2020,TwS
1070000111,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",11,with Index date: Jan 2020,TwS
1071000111,1071,prazosin,11,with Index date: Jan 2020,TwS
1072000111,1072,terazosin,11,with Index date: Jan 2020,TwS
1073000111,1073,doxazosin,11,with Index date: Jan 2020,TwS
1074000111,1074,tamsulosin,11,with Index date: Jan 2020,TwS
1075000111,1075,BCG vaccine,11,with Index date: Jan 2020,TwS
1076000111,1076,Colchicine,11,with Index date: Jan 2020,TwS
1077000111,1077,Losartan,11,with Index date: Jan 2020,TwS
1078000111,1078,cholecalciferol,11,with Index date: Jan 2020,TwS
1079000111,1079,Ibrutinib,11,with Index date: Jan 2020,TwS
1080000111,1080,abiraterone,11,with Index date: Jan 2020,TwS
1081000111,1081,bicalutamide,11,with Index date: Jan 2020,TwS
1082000111,1082,emtricitabine,11,with Index date: Jan 2020,TwS
1083000111,1083,tacrolimus,11,with Index date: Jan 2020,TwS
1001000121,1001,Hydroxychloroquine ,12,with Index date: Feb 2020,TwS
1002000121,1002,Hydroxychloroquine + Azithromycin ,12,with Index date: Feb 2020,TwS
1003000121,1003,Hydroxychloroquine + Fluoroquinolones,12,with Index date: Feb 2020,TwS
1004000121,1004,Hydroxychloroquine + Amoxicillin,12,with Index date: Feb 2020,TwS
1005000121,1005,Hydroxychloroquine + ceftriaxone,12,with Index date: Feb 2020,TwS
1006000121,1006,Chloroquine,12,with Index date: Feb 2020,TwS
1007000121,1007,Azithromycin,12,with Index date: Feb 2020,TwS
1008000121,1008,Fluoroquinolones,12,with Index date: Feb 2020,TwS
1009000121,1009,Amoxicillin,12,with Index date: Feb 2020,TwS
1010000121,1010,Ceftriaxone,12,with Index date: Feb 2020,TwS
1011000121,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",12,with Index date: Feb 2020,TwS
1012000121,1012,tocilizumab,12,with Index date: Feb 2020,TwS
1013000121,1013,siltuximab,12,with Index date: Feb 2020,TwS
1014000121,1014,sarilumab,12,with Index date: Feb 2020,TwS
1015000121,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",12,with Index date: Feb 2020,TwS
1016000121,1016,baricitinib,12,with Index date: Feb 2020,TwS
1017000121,1017,tofacitinib,12,with Index date: Feb 2020,TwS
1018000121,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",12,with Index date: Feb 2020,TwS
1019000121,1019,adalimumab,12,with Index date: Feb 2020,TwS
1020000121,1020,etanercept,12,with Index date: Feb 2020,TwS
1021000121,1021,infliximab,12,with Index date: Feb 2020,TwS
1022000121,1022,ustekinumab,12,with Index date: Feb 2020,TwS
1023000121,1023,Anakinra,12,with Index date: Feb 2020,TwS
1024000121,1024,HIV Protease inhibitors,12,with Index date: Feb 2020,TwS
1025000121,1025,ritonavir/lopinavir,12,with Index date: Feb 2020,TwS
1026000121,1026,Interferon beta 1b,12,with Index date: Feb 2020,TwS
1027000121,1027,Interferon beta 1a,12,with Index date: Feb 2020,TwS
1028000121,1028,Interferon alfa 2a,12,with Index date: Feb 2020,TwS
1029000121,1029,favipiravir,12,with Index date: Feb 2020,TwS
1030000121,1030,Remdesivir,12,with Index date: Feb 2020,TwS
1031000121,1031,ribavirin,12,with Index date: Feb 2020,TwS
1032000121,1032,oseltamivir,12,with Index date: Feb 2020,TwS
1033000121,1033,Ivermectin,12,with Index date: Feb 2020,TwS
1034000121,1034,itraconazole,12,with Index date: Feb 2020,TwS
1035000121,1035,warfarin,12,with Index date: Feb 2020,TwS
1036000121,1036,heparin,12,with Index date: Feb 2020,TwS
1037000121,1037,enoxaparin,12,with Index date: Feb 2020,TwS
1038000121,1038,edoxaban,12,with Index date: Feb 2020,TwS
1039000121,1039,dabigatran,12,with Index date: Feb 2020,TwS
1040000121,1040,rivaroxaban,12,with Index date: Feb 2020,TwS
1041000121,1041,acenocoumarol,12,with Index date: Feb 2020,TwS
1042000121,1042,apixaban,12,with Index date: Feb 2020,TwS
1043000121,1043,bemiparin,12,with Index date: Feb 2020,TwS
1044000121,1044,clopidogrel,12,with Index date: Feb 2020,TwS
1045000121,1045,aspirin,12,with Index date: Feb 2020,TwS
1046000121,1046,prasugrel,12,with Index date: Feb 2020,TwS
1047000121,1047,alteplase,12,with Index date: Feb 2020,TwS
1048000121,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",12,with Index date: Feb 2020,TwS
1049000121,1049,tranexamic acid,12,with Index date: Feb 2020,TwS
1050000121,1050,Ruxolitinib,12,with Index date: Feb 2020,TwS
1051000121,1051,Siltuximab,12,with Index date: Feb 2020,TwS
1052000121,1052,ACE inhibitors,12,with Index date: Feb 2020,TwS
1053000121,1053,Angiotensin receptor blockers (ARBs),12,with Index date: Feb 2020,TwS
1054000121,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),12,with Index date: Feb 2020,TwS
1055000121,1055,Thiazide or thiazide-like diuretics,12,with Index date: Feb 2020,TwS
1056000121,1056,Hydrocortisone,12,with Index date: Feb 2020,TwS
1057000121,1057,dexamethasone,12,with Index date: Feb 2020,TwS
1058000121,1058,prednisone or prednisolone,12,with Index date: Feb 2020,TwS
1059000121,1059,raloxifene,12,with Index date: Feb 2020,TwS
1060000121,1060,Bevacizumab,12,with Index date: Feb 2020,TwS
1061000121,1061,Fingolimod,12,with Index date: Feb 2020,TwS
1062000121,1062,eculizumab ,12,with Index date: Feb 2020,TwS
1063000121,1063,Statins,12,with Index date: Feb 2020,TwS
1064000121,1064,metformin,12,with Index date: Feb 2020,TwS
1065000121,1065,DPP-4 inhibitors,12,with Index date: Feb 2020,TwS
1066000121,1066,SGLT2 inhibitors,12,with Index date: Feb 2020,TwS
1067000121,1067,GLP1 inhibitors,12,with Index date: Feb 2020,TwS
1068000121,1068,H2 receptor antagonist,12,with Index date: Feb 2020,TwS
1069000121,1069,famotidine,12,with Index date: Feb 2020,TwS
1070000121,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",12,with Index date: Feb 2020,TwS
1071000121,1071,prazosin,12,with Index date: Feb 2020,TwS
1072000121,1072,terazosin,12,with Index date: Feb 2020,TwS
1073000121,1073,doxazosin,12,with Index date: Feb 2020,TwS
1074000121,1074,tamsulosin,12,with Index date: Feb 2020,TwS
1075000121,1075,BCG vaccine,12,with Index date: Feb 2020,TwS
1076000121,1076,Colchicine,12,with Index date: Feb 2020,TwS
1077000121,1077,Losartan,12,with Index date: Feb 2020,TwS
1078000121,1078,cholecalciferol,12,with Index date: Feb 2020,TwS
1079000121,1079,Ibrutinib,12,with Index date: Feb 2020,TwS
1080000121,1080,abiraterone,12,with Index date: Feb 2020,TwS
1081000121,1081,bicalutamide,12,with Index date: Feb 2020,TwS
1082000121,1082,emtricitabine,12,with Index date: Feb 2020,TwS
1083000121,1083,tacrolimus,12,with Index date: Feb 2020,TwS
1001000131,1001,Hydroxychloroquine ,13,with Index date: Mar 2020,TwS
1002000131,1002,Hydroxychloroquine + Azithromycin ,13,with Index date: Mar 2020,TwS
1003000131,1003,Hydroxychloroquine + Fluoroquinolones,13,with Index date: Mar 2020,TwS
1004000131,1004,Hydroxychloroquine + Amoxicillin,13,with Index date: Mar 2020,TwS
1005000131,1005,Hydroxychloroquine + ceftriaxone,13,with Index date: Mar 2020,TwS
1006000131,1006,Chloroquine,13,with Index date: Mar 2020,TwS
1007000131,1007,Azithromycin,13,with Index date: Mar 2020,TwS
1008000131,1008,Fluoroquinolones,13,with Index date: Mar 2020,TwS
1009000131,1009,Amoxicillin,13,with Index date: Mar 2020,TwS
1010000131,1010,Ceftriaxone,13,with Index date: Mar 2020,TwS
1011000131,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",13,with Index date: Mar 2020,TwS
1012000131,1012,tocilizumab,13,with Index date: Mar 2020,TwS
1013000131,1013,siltuximab,13,with Index date: Mar 2020,TwS
1014000131,1014,sarilumab,13,with Index date: Mar 2020,TwS
1015000131,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",13,with Index date: Mar 2020,TwS
1016000131,1016,baricitinib,13,with Index date: Mar 2020,TwS
1017000131,1017,tofacitinib,13,with Index date: Mar 2020,TwS
1018000131,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",13,with Index date: Mar 2020,TwS
1019000131,1019,adalimumab,13,with Index date: Mar 2020,TwS
1020000131,1020,etanercept,13,with Index date: Mar 2020,TwS
1021000131,1021,infliximab,13,with Index date: Mar 2020,TwS
1022000131,1022,ustekinumab,13,with Index date: Mar 2020,TwS
1023000131,1023,Anakinra,13,with Index date: Mar 2020,TwS
1024000131,1024,HIV Protease inhibitors,13,with Index date: Mar 2020,TwS
1025000131,1025,ritonavir/lopinavir,13,with Index date: Mar 2020,TwS
1026000131,1026,Interferon beta 1b,13,with Index date: Mar 2020,TwS
1027000131,1027,Interferon beta 1a,13,with Index date: Mar 2020,TwS
1028000131,1028,Interferon alfa 2a,13,with Index date: Mar 2020,TwS
1029000131,1029,favipiravir,13,with Index date: Mar 2020,TwS
1030000131,1030,Remdesivir,13,with Index date: Mar 2020,TwS
1031000131,1031,ribavirin,13,with Index date: Mar 2020,TwS
1032000131,1032,oseltamivir,13,with Index date: Mar 2020,TwS
1033000131,1033,Ivermectin,13,with Index date: Mar 2020,TwS
1034000131,1034,itraconazole,13,with Index date: Mar 2020,TwS
1035000131,1035,warfarin,13,with Index date: Mar 2020,TwS
1036000131,1036,heparin,13,with Index date: Mar 2020,TwS
1037000131,1037,enoxaparin,13,with Index date: Mar 2020,TwS
1038000131,1038,edoxaban,13,with Index date: Mar 2020,TwS
1039000131,1039,dabigatran,13,with Index date: Mar 2020,TwS
1040000131,1040,rivaroxaban,13,with Index date: Mar 2020,TwS
1041000131,1041,acenocoumarol,13,with Index date: Mar 2020,TwS
1042000131,1042,apixaban,13,with Index date: Mar 2020,TwS
1043000131,1043,bemiparin,13,with Index date: Mar 2020,TwS
1044000131,1044,clopidogrel,13,with Index date: Mar 2020,TwS
1045000131,1045,aspirin,13,with Index date: Mar 2020,TwS
1046000131,1046,prasugrel,13,with Index date: Mar 2020,TwS
1047000131,1047,alteplase,13,with Index date: Mar 2020,TwS
1048000131,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",13,with Index date: Mar 2020,TwS
1049000131,1049,tranexamic acid,13,with Index date: Mar 2020,TwS
1050000131,1050,Ruxolitinib,13,with Index date: Mar 2020,TwS
1051000131,1051,Siltuximab,13,with Index date: Mar 2020,TwS
1052000131,1052,ACE inhibitors,13,with Index date: Mar 2020,TwS
1053000131,1053,Angiotensin receptor blockers (ARBs),13,with Index date: Mar 2020,TwS
1054000131,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),13,with Index date: Mar 2020,TwS
1055000131,1055,Thiazide or thiazide-like diuretics,13,with Index date: Mar 2020,TwS
1056000131,1056,Hydrocortisone,13,with Index date: Mar 2020,TwS
1057000131,1057,dexamethasone,13,with Index date: Mar 2020,TwS
1058000131,1058,prednisone or prednisolone,13,with Index date: Mar 2020,TwS
1059000131,1059,raloxifene,13,with Index date: Mar 2020,TwS
1060000131,1060,Bevacizumab,13,with Index date: Mar 2020,TwS
1061000131,1061,Fingolimod,13,with Index date: Mar 2020,TwS
1062000131,1062,eculizumab ,13,with Index date: Mar 2020,TwS
1063000131,1063,Statins,13,with Index date: Mar 2020,TwS
1064000131,1064,metformin,13,with Index date: Mar 2020,TwS
1065000131,1065,DPP-4 inhibitors,13,with Index date: Mar 2020,TwS
1066000131,1066,SGLT2 inhibitors,13,with Index date: Mar 2020,TwS
1067000131,1067,GLP1 inhibitors,13,with Index date: Mar 2020,TwS
1068000131,1068,H2 receptor antagonist,13,with Index date: Mar 2020,TwS
1069000131,1069,famotidine,13,with Index date: Mar 2020,TwS
1070000131,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",13,with Index date: Mar 2020,TwS
1071000131,1071,prazosin,13,with Index date: Mar 2020,TwS
1072000131,1072,terazosin,13,with Index date: Mar 2020,TwS
1073000131,1073,doxazosin,13,with Index date: Mar 2020,TwS
1074000131,1074,tamsulosin,13,with Index date: Mar 2020,TwS
1075000131,1075,BCG vaccine,13,with Index date: Mar 2020,TwS
1076000131,1076,Colchicine,13,with Index date: Mar 2020,TwS
1077000131,1077,Losartan,13,with Index date: Mar 2020,TwS
1078000131,1078,cholecalciferol,13,with Index date: Mar 2020,TwS
1079000131,1079,Ibrutinib,13,with Index date: Mar 2020,TwS
1080000131,1080,abiraterone,13,with Index date: Mar 2020,TwS
1081000131,1081,bicalutamide,13,with Index date: Mar 2020,TwS
1082000131,1082,emtricitabine,13,with Index date: Mar 2020,TwS
1083000131,1083,tacrolimus,13,with Index date: Mar 2020,TwS
1001000141,1001,Hydroxychloroquine ,14,with Index date: Apr 2020,TwS
1002000141,1002,Hydroxychloroquine + Azithromycin ,14,with Index date: Apr 2020,TwS
1003000141,1003,Hydroxychloroquine + Fluoroquinolones,14,with Index date: Apr 2020,TwS
1004000141,1004,Hydroxychloroquine + Amoxicillin,14,with Index date: Apr 2020,TwS
1005000141,1005,Hydroxychloroquine + ceftriaxone,14,with Index date: Apr 2020,TwS
1006000141,1006,Chloroquine,14,with Index date: Apr 2020,TwS
1007000141,1007,Azithromycin,14,with Index date: Apr 2020,TwS
1008000141,1008,Fluoroquinolones,14,with Index date: Apr 2020,TwS
1009000141,1009,Amoxicillin,14,with Index date: Apr 2020,TwS
1010000141,1010,Ceftriaxone,14,with Index date: Apr 2020,TwS
1011000141,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",14,with Index date: Apr 2020,TwS
1012000141,1012,tocilizumab,14,with Index date: Apr 2020,TwS
1013000141,1013,siltuximab,14,with Index date: Apr 2020,TwS
1014000141,1014,sarilumab,14,with Index date: Apr 2020,TwS
1015000141,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",14,with Index date: Apr 2020,TwS
1016000141,1016,baricitinib,14,with Index date: Apr 2020,TwS
1017000141,1017,tofacitinib,14,with Index date: Apr 2020,TwS
1018000141,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",14,with Index date: Apr 2020,TwS
1019000141,1019,adalimumab,14,with Index date: Apr 2020,TwS
1020000141,1020,etanercept,14,with Index date: Apr 2020,TwS
1021000141,1021,infliximab,14,with Index date: Apr 2020,TwS
1022000141,1022,ustekinumab,14,with Index date: Apr 2020,TwS
1023000141,1023,Anakinra,14,with Index date: Apr 2020,TwS
1024000141,1024,HIV Protease inhibitors,14,with Index date: Apr 2020,TwS
1025000141,1025,ritonavir/lopinavir,14,with Index date: Apr 2020,TwS
1026000141,1026,Interferon beta 1b,14,with Index date: Apr 2020,TwS
1027000141,1027,Interferon beta 1a,14,with Index date: Apr 2020,TwS
1028000141,1028,Interferon alfa 2a,14,with Index date: Apr 2020,TwS
1029000141,1029,favipiravir,14,with Index date: Apr 2020,TwS
1030000141,1030,Remdesivir,14,with Index date: Apr 2020,TwS
1031000141,1031,ribavirin,14,with Index date: Apr 2020,TwS
1032000141,1032,oseltamivir,14,with Index date: Apr 2020,TwS
1033000141,1033,Ivermectin,14,with Index date: Apr 2020,TwS
1034000141,1034,itraconazole,14,with Index date: Apr 2020,TwS
1035000141,1035,warfarin,14,with Index date: Apr 2020,TwS
1036000141,1036,heparin,14,with Index date: Apr 2020,TwS
1037000141,1037,enoxaparin,14,with Index date: Apr 2020,TwS
1038000141,1038,edoxaban,14,with Index date: Apr 2020,TwS
1039000141,1039,dabigatran,14,with Index date: Apr 2020,TwS
1040000141,1040,rivaroxaban,14,with Index date: Apr 2020,TwS
1041000141,1041,acenocoumarol,14,with Index date: Apr 2020,TwS
1042000141,1042,apixaban,14,with Index date: Apr 2020,TwS
1043000141,1043,bemiparin,14,with Index date: Apr 2020,TwS
1044000141,1044,clopidogrel,14,with Index date: Apr 2020,TwS
1045000141,1045,aspirin,14,with Index date: Apr 2020,TwS
1046000141,1046,prasugrel,14,with Index date: Apr 2020,TwS
1047000141,1047,alteplase,14,with Index date: Apr 2020,TwS
1048000141,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",14,with Index date: Apr 2020,TwS
1049000141,1049,tranexamic acid,14,with Index date: Apr 2020,TwS
1050000141,1050,Ruxolitinib,14,with Index date: Apr 2020,TwS
1051000141,1051,Siltuximab,14,with Index date: Apr 2020,TwS
1052000141,1052,ACE inhibitors,14,with Index date: Apr 2020,TwS
1053000141,1053,Angiotensin receptor blockers (ARBs),14,with Index date: Apr 2020,TwS
1054000141,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),14,with Index date: Apr 2020,TwS
1055000141,1055,Thiazide or thiazide-like diuretics,14,with Index date: Apr 2020,TwS
1056000141,1056,Hydrocortisone,14,with Index date: Apr 2020,TwS
1057000141,1057,dexamethasone,14,with Index date: Apr 2020,TwS
1058000141,1058,prednisone or prednisolone,14,with Index date: Apr 2020,TwS
1059000141,1059,raloxifene,14,with Index date: Apr 2020,TwS
1060000141,1060,Bevacizumab,14,with Index date: Apr 2020,TwS
1061000141,1061,Fingolimod,14,with Index date: Apr 2020,TwS
1062000141,1062,eculizumab ,14,with Index date: Apr 2020,TwS
1063000141,1063,Statins,14,with Index date: Apr 2020,TwS
1064000141,1064,metformin,14,with Index date: Apr 2020,TwS
1065000141,1065,DPP-4 inhibitors,14,with Index date: Apr 2020,TwS
1066000141,1066,SGLT2 inhibitors,14,with Index date: Apr 2020,TwS
1067000141,1067,GLP1 inhibitors,14,with Index date: Apr 2020,TwS
1068000141,1068,H2 receptor antagonist,14,with Index date: Apr 2020,TwS
1069000141,1069,famotidine,14,with Index date: Apr 2020,TwS
1070000141,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",14,with Index date: Apr 2020,TwS
1071000141,1071,prazosin,14,with Index date: Apr 2020,TwS
1072000141,1072,terazosin,14,with Index date: Apr 2020,TwS
1073000141,1073,doxazosin,14,with Index date: Apr 2020,TwS
1074000141,1074,tamsulosin,14,with Index date: Apr 2020,TwS
1075000141,1075,BCG vaccine,14,with Index date: Apr 2020,TwS
1076000141,1076,Colchicine,14,with Index date: Apr 2020,TwS
1077000141,1077,Losartan,14,with Index date: Apr 2020,TwS
1078000141,1078,cholecalciferol,14,with Index date: Apr 2020,TwS
1079000141,1079,Ibrutinib,14,with Index date: Apr 2020,TwS
1080000141,1080,abiraterone,14,with Index date: Apr 2020,TwS
1081000141,1081,bicalutamide,14,with Index date: Apr 2020,TwS
1082000141,1082,emtricitabine,14,with Index date: Apr 2020,TwS
1083000141,1083,tacrolimus,14,with Index date: Apr 2020,TwS
1001000151,1001,Hydroxychloroquine ,15,with Index date: May 2020,TwS
1002000151,1002,Hydroxychloroquine + Azithromycin ,15,with Index date: May 2020,TwS
1003000151,1003,Hydroxychloroquine + Fluoroquinolones,15,with Index date: May 2020,TwS
1004000151,1004,Hydroxychloroquine + Amoxicillin,15,with Index date: May 2020,TwS
1005000151,1005,Hydroxychloroquine + ceftriaxone,15,with Index date: May 2020,TwS
1006000151,1006,Chloroquine,15,with Index date: May 2020,TwS
1007000151,1007,Azithromycin,15,with Index date: May 2020,TwS
1008000151,1008,Fluoroquinolones,15,with Index date: May 2020,TwS
1009000151,1009,Amoxicillin,15,with Index date: May 2020,TwS
1010000151,1010,Ceftriaxone,15,with Index date: May 2020,TwS
1011000151,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",15,with Index date: May 2020,TwS
1012000151,1012,tocilizumab,15,with Index date: May 2020,TwS
1013000151,1013,siltuximab,15,with Index date: May 2020,TwS
1014000151,1014,sarilumab,15,with Index date: May 2020,TwS
1015000151,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",15,with Index date: May 2020,TwS
1016000151,1016,baricitinib,15,with Index date: May 2020,TwS
1017000151,1017,tofacitinib,15,with Index date: May 2020,TwS
1018000151,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",15,with Index date: May 2020,TwS
1019000151,1019,adalimumab,15,with Index date: May 2020,TwS
1020000151,1020,etanercept,15,with Index date: May 2020,TwS
1021000151,1021,infliximab,15,with Index date: May 2020,TwS
1022000151,1022,ustekinumab,15,with Index date: May 2020,TwS
1023000151,1023,Anakinra,15,with Index date: May 2020,TwS
1024000151,1024,HIV Protease inhibitors,15,with Index date: May 2020,TwS
1025000151,1025,ritonavir/lopinavir,15,with Index date: May 2020,TwS
1026000151,1026,Interferon beta 1b,15,with Index date: May 2020,TwS
1027000151,1027,Interferon beta 1a,15,with Index date: May 2020,TwS
1028000151,1028,Interferon alfa 2a,15,with Index date: May 2020,TwS
1029000151,1029,favipiravir,15,with Index date: May 2020,TwS
1030000151,1030,Remdesivir,15,with Index date: May 2020,TwS
1031000151,1031,ribavirin,15,with Index date: May 2020,TwS
1032000151,1032,oseltamivir,15,with Index date: May 2020,TwS
1033000151,1033,Ivermectin,15,with Index date: May 2020,TwS
1034000151,1034,itraconazole,15,with Index date: May 2020,TwS
1035000151,1035,warfarin,15,with Index date: May 2020,TwS
1036000151,1036,heparin,15,with Index date: May 2020,TwS
1037000151,1037,enoxaparin,15,with Index date: May 2020,TwS
1038000151,1038,edoxaban,15,with Index date: May 2020,TwS
1039000151,1039,dabigatran,15,with Index date: May 2020,TwS
1040000151,1040,rivaroxaban,15,with Index date: May 2020,TwS
1041000151,1041,acenocoumarol,15,with Index date: May 2020,TwS
1042000151,1042,apixaban,15,with Index date: May 2020,TwS
1043000151,1043,bemiparin,15,with Index date: May 2020,TwS
1044000151,1044,clopidogrel,15,with Index date: May 2020,TwS
1045000151,1045,aspirin,15,with Index date: May 2020,TwS
1046000151,1046,prasugrel,15,with Index date: May 2020,TwS
1047000151,1047,alteplase,15,with Index date: May 2020,TwS
1048000151,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",15,with Index date: May 2020,TwS
1049000151,1049,tranexamic acid,15,with Index date: May 2020,TwS
1050000151,1050,Ruxolitinib,15,with Index date: May 2020,TwS
1051000151,1051,Siltuximab,15,with Index date: May 2020,TwS
1052000151,1052,ACE inhibitors,15,with Index date: May 2020,TwS
1053000151,1053,Angiotensin receptor blockers (ARBs),15,with Index date: May 2020,TwS
1054000151,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),15,with Index date: May 2020,TwS
1055000151,1055,Thiazide or thiazide-like diuretics,15,with Index date: May 2020,TwS
1056000151,1056,Hydrocortisone,15,with Index date: May 2020,TwS
1057000151,1057,dexamethasone,15,with Index date: May 2020,TwS
1058000151,1058,prednisone or prednisolone,15,with Index date: May 2020,TwS
1059000151,1059,raloxifene,15,with Index date: May 2020,TwS
1060000151,1060,Bevacizumab,15,with Index date: May 2020,TwS
1061000151,1061,Fingolimod,15,with Index date: May 2020,TwS
1062000151,1062,eculizumab ,15,with Index date: May 2020,TwS
1063000151,1063,Statins,15,with Index date: May 2020,TwS
1064000151,1064,metformin,15,with Index date: May 2020,TwS
1065000151,1065,DPP-4 inhibitors,15,with Index date: May 2020,TwS
1066000151,1066,SGLT2 inhibitors,15,with Index date: May 2020,TwS
1067000151,1067,GLP1 inhibitors,15,with Index date: May 2020,TwS
1068000151,1068,H2 receptor antagonist,15,with Index date: May 2020,TwS
1069000151,1069,famotidine,15,with Index date: May 2020,TwS
1070000151,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",15,with Index date: May 2020,TwS
1071000151,1071,prazosin,15,with Index date: May 2020,TwS
1072000151,1072,terazosin,15,with Index date: May 2020,TwS
1073000151,1073,doxazosin,15,with Index date: May 2020,TwS
1074000151,1074,tamsulosin,15,with Index date: May 2020,TwS
1075000151,1075,BCG vaccine,15,with Index date: May 2020,TwS
1076000151,1076,Colchicine,15,with Index date: May 2020,TwS
1077000151,1077,Losartan,15,with Index date: May 2020,TwS
1078000151,1078,cholecalciferol,15,with Index date: May 2020,TwS
1079000151,1079,Ibrutinib,15,with Index date: May 2020,TwS
1080000151,1080,abiraterone,15,with Index date: May 2020,TwS
1081000151,1081,bicalutamide,15,with Index date: May 2020,TwS
1082000151,1082,emtricitabine,15,with Index date: May 2020,TwS
1083000151,1083,tacrolimus,15,with Index date: May 2020,TwS
1001000161,1001,Hydroxychloroquine ,16,with Index date: Jun 2020,TwS
1002000161,1002,Hydroxychloroquine + Azithromycin ,16,with Index date: Jun 2020,TwS
1003000161,1003,Hydroxychloroquine + Fluoroquinolones,16,with Index date: Jun 2020,TwS
1004000161,1004,Hydroxychloroquine + Amoxicillin,16,with Index date: Jun 2020,TwS
1005000161,1005,Hydroxychloroquine + ceftriaxone,16,with Index date: Jun 2020,TwS
1006000161,1006,Chloroquine,16,with Index date: Jun 2020,TwS
1007000161,1007,Azithromycin,16,with Index date: Jun 2020,TwS
1008000161,1008,Fluoroquinolones,16,with Index date: Jun 2020,TwS
1009000161,1009,Amoxicillin,16,with Index date: Jun 2020,TwS
1010000161,1010,Ceftriaxone,16,with Index date: Jun 2020,TwS
1011000161,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",16,with Index date: Jun 2020,TwS
1012000161,1012,tocilizumab,16,with Index date: Jun 2020,TwS
1013000161,1013,siltuximab,16,with Index date: Jun 2020,TwS
1014000161,1014,sarilumab,16,with Index date: Jun 2020,TwS
1015000161,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",16,with Index date: Jun 2020,TwS
1016000161,1016,baricitinib,16,with Index date: Jun 2020,TwS
1017000161,1017,tofacitinib,16,with Index date: Jun 2020,TwS
1018000161,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",16,with Index date: Jun 2020,TwS
1019000161,1019,adalimumab,16,with Index date: Jun 2020,TwS
1020000161,1020,etanercept,16,with Index date: Jun 2020,TwS
1021000161,1021,infliximab,16,with Index date: Jun 2020,TwS
1022000161,1022,ustekinumab,16,with Index date: Jun 2020,TwS
1023000161,1023,Anakinra,16,with Index date: Jun 2020,TwS
1024000161,1024,HIV Protease inhibitors,16,with Index date: Jun 2020,TwS
1025000161,1025,ritonavir/lopinavir,16,with Index date: Jun 2020,TwS
1026000161,1026,Interferon beta 1b,16,with Index date: Jun 2020,TwS
1027000161,1027,Interferon beta 1a,16,with Index date: Jun 2020,TwS
1028000161,1028,Interferon alfa 2a,16,with Index date: Jun 2020,TwS
1029000161,1029,favipiravir,16,with Index date: Jun 2020,TwS
1030000161,1030,Remdesivir,16,with Index date: Jun 2020,TwS
1031000161,1031,ribavirin,16,with Index date: Jun 2020,TwS
1032000161,1032,oseltamivir,16,with Index date: Jun 2020,TwS
1033000161,1033,Ivermectin,16,with Index date: Jun 2020,TwS
1034000161,1034,itraconazole,16,with Index date: Jun 2020,TwS
1035000161,1035,warfarin,16,with Index date: Jun 2020,TwS
1036000161,1036,heparin,16,with Index date: Jun 2020,TwS
1037000161,1037,enoxaparin,16,with Index date: Jun 2020,TwS
1038000161,1038,edoxaban,16,with Index date: Jun 2020,TwS
1039000161,1039,dabigatran,16,with Index date: Jun 2020,TwS
1040000161,1040,rivaroxaban,16,with Index date: Jun 2020,TwS
1041000161,1041,acenocoumarol,16,with Index date: Jun 2020,TwS
1042000161,1042,apixaban,16,with Index date: Jun 2020,TwS
1043000161,1043,bemiparin,16,with Index date: Jun 2020,TwS
1044000161,1044,clopidogrel,16,with Index date: Jun 2020,TwS
1045000161,1045,aspirin,16,with Index date: Jun 2020,TwS
1046000161,1046,prasugrel,16,with Index date: Jun 2020,TwS
1047000161,1047,alteplase,16,with Index date: Jun 2020,TwS
1048000161,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",16,with Index date: Jun 2020,TwS
1049000161,1049,tranexamic acid,16,with Index date: Jun 2020,TwS
1050000161,1050,Ruxolitinib,16,with Index date: Jun 2020,TwS
1051000161,1051,Siltuximab,16,with Index date: Jun 2020,TwS
1052000161,1052,ACE inhibitors,16,with Index date: Jun 2020,TwS
1053000161,1053,Angiotensin receptor blockers (ARBs),16,with Index date: Jun 2020,TwS
1054000161,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),16,with Index date: Jun 2020,TwS
1055000161,1055,Thiazide or thiazide-like diuretics,16,with Index date: Jun 2020,TwS
1056000161,1056,Hydrocortisone,16,with Index date: Jun 2020,TwS
1057000161,1057,dexamethasone,16,with Index date: Jun 2020,TwS
1058000161,1058,prednisone or prednisolone,16,with Index date: Jun 2020,TwS
1059000161,1059,raloxifene,16,with Index date: Jun 2020,TwS
1060000161,1060,Bevacizumab,16,with Index date: Jun 2020,TwS
1061000161,1061,Fingolimod,16,with Index date: Jun 2020,TwS
1062000161,1062,eculizumab ,16,with Index date: Jun 2020,TwS
1063000161,1063,Statins,16,with Index date: Jun 2020,TwS
1064000161,1064,metformin,16,with Index date: Jun 2020,TwS
1065000161,1065,DPP-4 inhibitors,16,with Index date: Jun 2020,TwS
1066000161,1066,SGLT2 inhibitors,16,with Index date: Jun 2020,TwS
1067000161,1067,GLP1 inhibitors,16,with Index date: Jun 2020,TwS
1068000161,1068,H2 receptor antagonist,16,with Index date: Jun 2020,TwS
1069000161,1069,famotidine,16,with Index date: Jun 2020,TwS
1070000161,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",16,with Index date: Jun 2020,TwS
1071000161,1071,prazosin,16,with Index date: Jun 2020,TwS
1072000161,1072,terazosin,16,with Index date: Jun 2020,TwS
1073000161,1073,doxazosin,16,with Index date: Jun 2020,TwS
1074000161,1074,tamsulosin,16,with Index date: Jun 2020,TwS
1075000161,1075,BCG vaccine,16,with Index date: Jun 2020,TwS
1076000161,1076,Colchicine,16,with Index date: Jun 2020,TwS
1077000161,1077,Losartan,16,with Index date: Jun 2020,TwS
1078000161,1078,cholecalciferol,16,with Index date: Jun 2020,TwS
1079000161,1079,Ibrutinib,16,with Index date: Jun 2020,TwS
1080000161,1080,abiraterone,16,with Index date: Jun 2020,TwS
1081000161,1081,bicalutamide,16,with Index date: Jun 2020,TwS
1082000161,1082,emtricitabine,16,with Index date: Jun 2020,TwS
1083000161,1083,tacrolimus,16,with Index date: Jun 2020,TwS
1001020011,1001,Hydroxychloroquine ,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1002020011,1002,Hydroxychloroquine + Azithromycin ,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1003020011,1003,Hydroxychloroquine + Fluoroquinolones,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1004020011,1004,Hydroxychloroquine + Amoxicillin,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1005020011,1005,Hydroxychloroquine + ceftriaxone,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1006020011,1006,Chloroquine,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1007020011,1007,Azithromycin,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1008020011,1008,Fluoroquinolones,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1009020011,1009,Amoxicillin,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1010020011,1010,Ceftriaxone,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1011020011,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1012020011,1012,tocilizumab,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1013020011,1013,siltuximab,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1014020011,1014,sarilumab,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1015020011,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1016020011,1016,baricitinib,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1017020011,1017,tofacitinib,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1018020011,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1019020011,1019,adalimumab,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1020020011,1020,etanercept,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1021020011,1021,infliximab,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1022020011,1022,ustekinumab,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1023020011,1023,Anakinra,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1024020011,1024,HIV Protease inhibitors,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1025020011,1025,ritonavir/lopinavir,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1026020011,1026,Interferon beta 1b,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1027020011,1027,Interferon beta 1a,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1028020011,1028,Interferon alfa 2a,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1029020011,1029,favipiravir,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1030020011,1030,Remdesivir,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1031020011,1031,ribavirin,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1032020011,1032,oseltamivir,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1033020011,1033,Ivermectin,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1034020011,1034,itraconazole,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1035020011,1035,warfarin,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1036020011,1036,heparin,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1037020011,1037,enoxaparin,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1038020011,1038,edoxaban,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1039020011,1039,dabigatran,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1040020011,1040,rivaroxaban,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1041020011,1041,acenocoumarol,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1042020011,1042,apixaban,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1043020011,1043,bemiparin,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1044020011,1044,clopidogrel,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1045020011,1045,aspirin,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1046020011,1046,prasugrel,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1047020011,1047,alteplase,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1048020011,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1049020011,1049,tranexamic acid,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1050020011,1050,Ruxolitinib,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1051020011,1051,Siltuximab,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1052020011,1052,ACE inhibitors,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1053020011,1053,Angiotensin receptor blockers (ARBs),2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1054020011,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1055020011,1055,Thiazide or thiazide-like diuretics,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1056020011,1056,Hydrocortisone,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1057020011,1057,dexamethasone,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1058020011,1058,prednisone or prednisolone,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1059020011,1059,raloxifene,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1060020011,1060,Bevacizumab,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1061020011,1061,Fingolimod,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1062020011,1062,eculizumab ,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1063020011,1063,Statins,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1064020011,1064,metformin,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1065020011,1065,DPP-4 inhibitors,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1066020011,1066,SGLT2 inhibitors,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1067020011,1067,GLP1 inhibitors,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1068020011,1068,H2 receptor antagonist,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1069020011,1069,famotidine,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1070020011,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1071020011,1071,prazosin,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1072020011,1072,terazosin,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1073020011,1073,doxazosin,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1074020011,1074,tamsulosin,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1075020011,1075,BCG vaccine,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1076020011,1076,Colchicine,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1077020011,1077,Losartan,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1078020011,1078,cholecalciferol,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1079020011,1079,Ibrutinib,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1080020011,1080,abiraterone,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1081020011,1081,bicalutamide,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1082020011,1082,emtricitabine,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1083020011,1083,tacrolimus,2001,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1001020021,1001,Hydroxychloroquine ,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1002020021,1002,Hydroxychloroquine + Azithromycin ,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1003020021,1003,Hydroxychloroquine + Fluoroquinolones,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1004020021,1004,Hydroxychloroquine + Amoxicillin,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1005020021,1005,Hydroxychloroquine + ceftriaxone,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1006020021,1006,Chloroquine,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1007020021,1007,Azithromycin,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1008020021,1008,Fluoroquinolones,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1009020021,1009,Amoxicillin,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1010020021,1010,Ceftriaxone,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1011020021,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1012020021,1012,tocilizumab,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1013020021,1013,siltuximab,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1014020021,1014,sarilumab,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1015020021,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1016020021,1016,baricitinib,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1017020021,1017,tofacitinib,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1018020021,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1019020021,1019,adalimumab,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1020020021,1020,etanercept,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1021020021,1021,infliximab,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1022020021,1022,ustekinumab,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1023020021,1023,Anakinra,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1024020021,1024,HIV Protease inhibitors,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1025020021,1025,ritonavir/lopinavir,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1026020021,1026,Interferon beta 1b,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1027020021,1027,Interferon beta 1a,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1028020021,1028,Interferon alfa 2a,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1029020021,1029,favipiravir,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1030020021,1030,Remdesivir,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1031020021,1031,ribavirin,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1032020021,1032,oseltamivir,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1033020021,1033,Ivermectin,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1034020021,1034,itraconazole,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1035020021,1035,warfarin,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1036020021,1036,heparin,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1037020021,1037,enoxaparin,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1038020021,1038,edoxaban,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1039020021,1039,dabigatran,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1040020021,1040,rivaroxaban,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1041020021,1041,acenocoumarol,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1042020021,1042,apixaban,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1043020021,1043,bemiparin,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1044020021,1044,clopidogrel,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1045020021,1045,aspirin,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1046020021,1046,prasugrel,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1047020021,1047,alteplase,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1048020021,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1049020021,1049,tranexamic acid,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1050020021,1050,Ruxolitinib,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1051020021,1051,Siltuximab,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1052020021,1052,ACE inhibitors,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1053020021,1053,Angiotensin receptor blockers (ARBs),2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1054020021,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1055020021,1055,Thiazide or thiazide-like diuretics,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1056020021,1056,Hydrocortisone,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1057020021,1057,dexamethasone,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1058020021,1058,prednisone or prednisolone,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1059020021,1059,raloxifene,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1060020021,1060,Bevacizumab,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1061020021,1061,Fingolimod,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1062020021,1062,eculizumab ,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1063020021,1063,Statins,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1064020021,1064,metformin,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1065020021,1065,DPP-4 inhibitors,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1066020021,1066,SGLT2 inhibitors,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1067020021,1067,GLP1 inhibitors,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1068020021,1068,H2 receptor antagonist,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1069020021,1069,famotidine,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1070020021,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1071020021,1071,prazosin,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1072020021,1072,terazosin,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1073020021,1073,doxazosin,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1074020021,1074,tamsulosin,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1075020021,1075,BCG vaccine,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1076020021,1076,Colchicine,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1077020021,1077,Losartan,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1078020021,1078,cholecalciferol,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1079020021,1079,Ibrutinib,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1080020021,1080,abiraterone,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1081020021,1081,bicalutamide,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1082020021,1082,emtricitabine,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1083020021,1083,tacrolimus,2002,with  Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1001020031,1001,Hydroxychloroquine ,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1002020031,1002,Hydroxychloroquine + Azithromycin ,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1003020031,1003,Hydroxychloroquine + Fluoroquinolones,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1004020031,1004,Hydroxychloroquine + Amoxicillin,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1005020031,1005,Hydroxychloroquine + ceftriaxone,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1006020031,1006,Chloroquine,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1007020031,1007,Azithromycin,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1008020031,1008,Fluoroquinolones,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1009020031,1009,Amoxicillin,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1010020031,1010,Ceftriaxone,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1011020031,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1012020031,1012,tocilizumab,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1013020031,1013,siltuximab,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1014020031,1014,sarilumab,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1015020031,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1016020031,1016,baricitinib,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1017020031,1017,tofacitinib,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1018020031,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1019020031,1019,adalimumab,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1020020031,1020,etanercept,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1021020031,1021,infliximab,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1022020031,1022,ustekinumab,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1023020031,1023,Anakinra,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1024020031,1024,HIV Protease inhibitors,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1025020031,1025,ritonavir/lopinavir,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1026020031,1026,Interferon beta 1b,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1027020031,1027,Interferon beta 1a,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1028020031,1028,Interferon alfa 2a,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1029020031,1029,favipiravir,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1030020031,1030,Remdesivir,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1031020031,1031,ribavirin,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1032020031,1032,oseltamivir,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1033020031,1033,Ivermectin,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1034020031,1034,itraconazole,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1035020031,1035,warfarin,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1036020031,1036,heparin,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1037020031,1037,enoxaparin,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1038020031,1038,edoxaban,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1039020031,1039,dabigatran,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1040020031,1040,rivaroxaban,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1041020031,1041,acenocoumarol,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1042020031,1042,apixaban,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1043020031,1043,bemiparin,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1044020031,1044,clopidogrel,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1045020031,1045,aspirin,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1046020031,1046,prasugrel,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1047020031,1047,alteplase,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1048020031,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1049020031,1049,tranexamic acid,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1050020031,1050,Ruxolitinib,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1051020031,1051,Siltuximab,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1052020031,1052,ACE inhibitors,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1053020031,1053,Angiotensin receptor blockers (ARBs),2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1054020031,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1055020031,1055,Thiazide or thiazide-like diuretics,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1056020031,1056,Hydrocortisone,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1057020031,1057,dexamethasone,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1058020031,1058,prednisone or prednisolone,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1059020031,1059,raloxifene,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1060020031,1060,Bevacizumab,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1061020031,1061,Fingolimod,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1062020031,1062,eculizumab ,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1063020031,1063,Statins,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1064020031,1064,metformin,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1065020031,1065,DPP-4 inhibitors,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1066020031,1066,SGLT2 inhibitors,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1067020031,1067,GLP1 inhibitors,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1068020031,1068,H2 receptor antagonist,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1069020031,1069,famotidine,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1070020031,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1071020031,1071,prazosin,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1072020031,1072,terazosin,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1073020031,1073,doxazosin,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1074020031,1074,tamsulosin,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1075020031,1075,BCG vaccine,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1076020031,1076,Colchicine,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1077020031,1077,Losartan,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1078020031,1078,cholecalciferol,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1079020031,1079,Ibrutinib,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1080020031,1080,abiraterone,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1081020031,1081,bicalutamide,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1082020031,1082,emtricitabine,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1083020031,1083,tacrolimus,2003,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1001020041,1001,Hydroxychloroquine ,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1002020041,1002,Hydroxychloroquine + Azithromycin ,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1003020041,1003,Hydroxychloroquine + Fluoroquinolones,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1004020041,1004,Hydroxychloroquine + Amoxicillin,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1005020041,1005,Hydroxychloroquine + ceftriaxone,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1006020041,1006,Chloroquine,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1007020041,1007,Azithromycin,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1008020041,1008,Fluoroquinolones,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1009020041,1009,Amoxicillin,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1010020041,1010,Ceftriaxone,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1011020041,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1012020041,1012,tocilizumab,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1013020041,1013,siltuximab,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1014020041,1014,sarilumab,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1015020041,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1016020041,1016,baricitinib,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1017020041,1017,tofacitinib,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1018020041,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1019020041,1019,adalimumab,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1020020041,1020,etanercept,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1021020041,1021,infliximab,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1022020041,1022,ustekinumab,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1023020041,1023,Anakinra,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1024020041,1024,HIV Protease inhibitors,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1025020041,1025,ritonavir/lopinavir,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1026020041,1026,Interferon beta 1b,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1027020041,1027,Interferon beta 1a,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1028020041,1028,Interferon alfa 2a,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1029020041,1029,favipiravir,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1030020041,1030,Remdesivir,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1031020041,1031,ribavirin,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1032020041,1032,oseltamivir,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1033020041,1033,Ivermectin,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1034020041,1034,itraconazole,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1035020041,1035,warfarin,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1036020041,1036,heparin,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1037020041,1037,enoxaparin,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1038020041,1038,edoxaban,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1039020041,1039,dabigatran,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1040020041,1040,rivaroxaban,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1041020041,1041,acenocoumarol,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1042020041,1042,apixaban,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1043020041,1043,bemiparin,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1044020041,1044,clopidogrel,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1045020041,1045,aspirin,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1046020041,1046,prasugrel,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1047020041,1047,alteplase,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1048020041,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1049020041,1049,tranexamic acid,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1050020041,1050,Ruxolitinib,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1051020041,1051,Siltuximab,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1052020041,1052,ACE inhibitors,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1053020041,1053,Angiotensin receptor blockers (ARBs),2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1054020041,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1055020041,1055,Thiazide or thiazide-like diuretics,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1056020041,1056,Hydrocortisone,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1057020041,1057,dexamethasone,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1058020041,1058,prednisone or prednisolone,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1059020041,1059,raloxifene,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1060020041,1060,Bevacizumab,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1061020041,1061,Fingolimod,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1062020041,1062,eculizumab ,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1063020041,1063,Statins,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1064020041,1064,metformin,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1065020041,1065,DPP-4 inhibitors,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1066020041,1066,SGLT2 inhibitors,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1067020041,1067,GLP1 inhibitors,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1068020041,1068,H2 receptor antagonist,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1069020041,1069,famotidine,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1070020041,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1071020041,1071,prazosin,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1072020041,1072,terazosin,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1073020041,1073,doxazosin,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1074020041,1074,tamsulosin,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1075020041,1075,BCG vaccine,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1076020041,1076,Colchicine,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1077020041,1077,Losartan,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1078020041,1078,cholecalciferol,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1079020041,1079,Ibrutinib,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1080020041,1080,abiraterone,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1081020041,1081,bicalutamide,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1082020041,1082,emtricitabine,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1083020041,1083,tacrolimus,2004,"with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1001020051,1001,Hydroxychloroquine ,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1002020051,1002,Hydroxychloroquine + Azithromycin ,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1003020051,1003,Hydroxychloroquine + Fluoroquinolones,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1004020051,1004,Hydroxychloroquine + Amoxicillin,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1005020051,1005,Hydroxychloroquine + ceftriaxone,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1006020051,1006,Chloroquine,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1007020051,1007,Azithromycin,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1008020051,1008,Fluoroquinolones,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1009020051,1009,Amoxicillin,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1010020051,1010,Ceftriaxone,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1011020051,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1012020051,1012,tocilizumab,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1013020051,1013,siltuximab,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1014020051,1014,sarilumab,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1015020051,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1016020051,1016,baricitinib,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1017020051,1017,tofacitinib,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1018020051,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1019020051,1019,adalimumab,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1020020051,1020,etanercept,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1021020051,1021,infliximab,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1022020051,1022,ustekinumab,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1023020051,1023,Anakinra,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1024020051,1024,HIV Protease inhibitors,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1025020051,1025,ritonavir/lopinavir,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1026020051,1026,Interferon beta 1b,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1027020051,1027,Interferon beta 1a,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1028020051,1028,Interferon alfa 2a,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1029020051,1029,favipiravir,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1030020051,1030,Remdesivir,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1031020051,1031,ribavirin,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1032020051,1032,oseltamivir,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1033020051,1033,Ivermectin,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1034020051,1034,itraconazole,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1035020051,1035,warfarin,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1036020051,1036,heparin,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1037020051,1037,enoxaparin,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1038020051,1038,edoxaban,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1039020051,1039,dabigatran,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1040020051,1040,rivaroxaban,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1041020051,1041,acenocoumarol,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1042020051,1042,apixaban,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1043020051,1043,bemiparin,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1044020051,1044,clopidogrel,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1045020051,1045,aspirin,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1046020051,1046,prasugrel,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1047020051,1047,alteplase,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1048020051,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1049020051,1049,tranexamic acid,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1050020051,1050,Ruxolitinib,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1051020051,1051,Siltuximab,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1052020051,1052,ACE inhibitors,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1053020051,1053,Angiotensin receptor blockers (ARBs),2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1054020051,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1055020051,1055,Thiazide or thiazide-like diuretics,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1056020051,1056,Hydrocortisone,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1057020051,1057,dexamethasone,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1058020051,1058,prednisone or prednisolone,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1059020051,1059,raloxifene,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1060020051,1060,Bevacizumab,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1061020051,1061,Fingolimod,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1062020051,1062,eculizumab ,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1063020051,1063,Statins,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1064020051,1064,metformin,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1065020051,1065,DPP-4 inhibitors,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1066020051,1066,SGLT2 inhibitors,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1067020051,1067,GLP1 inhibitors,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1068020051,1068,H2 receptor antagonist,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1069020051,1069,famotidine,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1070020051,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1071020051,1071,prazosin,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1072020051,1072,terazosin,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1073020051,1073,doxazosin,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1074020051,1074,tamsulosin,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1075020051,1075,BCG vaccine,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1076020051,1076,Colchicine,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1077020051,1077,Losartan,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1078020051,1078,cholecalciferol,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1079020051,1079,Ibrutinib,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1080020051,1080,abiraterone,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1081020051,1081,bicalutamide,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1082020051,1082,emtricitabine,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1083020051,1083,tacrolimus,2005,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1001020061,1001,Hydroxychloroquine ,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1002020061,1002,Hydroxychloroquine + Azithromycin ,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1003020061,1003,Hydroxychloroquine + Fluoroquinolones,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1004020061,1004,Hydroxychloroquine + Amoxicillin,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1005020061,1005,Hydroxychloroquine + ceftriaxone,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1006020061,1006,Chloroquine,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1007020061,1007,Azithromycin,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1008020061,1008,Fluoroquinolones,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1009020061,1009,Amoxicillin,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1010020061,1010,Ceftriaxone,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1011020061,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1012020061,1012,tocilizumab,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1013020061,1013,siltuximab,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1014020061,1014,sarilumab,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1015020061,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1016020061,1016,baricitinib,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1017020061,1017,tofacitinib,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1018020061,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1019020061,1019,adalimumab,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1020020061,1020,etanercept,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1021020061,1021,infliximab,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1022020061,1022,ustekinumab,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1023020061,1023,Anakinra,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1024020061,1024,HIV Protease inhibitors,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1025020061,1025,ritonavir/lopinavir,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1026020061,1026,Interferon beta 1b,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1027020061,1027,Interferon beta 1a,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1028020061,1028,Interferon alfa 2a,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1029020061,1029,favipiravir,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1030020061,1030,Remdesivir,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1031020061,1031,ribavirin,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1032020061,1032,oseltamivir,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1033020061,1033,Ivermectin,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1034020061,1034,itraconazole,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1035020061,1035,warfarin,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1036020061,1036,heparin,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1037020061,1037,enoxaparin,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1038020061,1038,edoxaban,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1039020061,1039,dabigatran,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1040020061,1040,rivaroxaban,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1041020061,1041,acenocoumarol,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1042020061,1042,apixaban,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1043020061,1043,bemiparin,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1044020061,1044,clopidogrel,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1045020061,1045,aspirin,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1046020061,1046,prasugrel,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1047020061,1047,alteplase,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1048020061,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1049020061,1049,tranexamic acid,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1050020061,1050,Ruxolitinib,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1051020061,1051,Siltuximab,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1052020061,1052,ACE inhibitors,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1053020061,1053,Angiotensin receptor blockers (ARBs),2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1054020061,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1055020061,1055,Thiazide or thiazide-like diuretics,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1056020061,1056,Hydrocortisone,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1057020061,1057,dexamethasone,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1058020061,1058,prednisone or prednisolone,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1059020061,1059,raloxifene,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1060020061,1060,Bevacizumab,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1061020061,1061,Fingolimod,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1062020061,1062,eculizumab ,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1063020061,1063,Statins,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1064020061,1064,metformin,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1065020061,1065,DPP-4 inhibitors,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1066020061,1066,SGLT2 inhibitors,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1067020061,1067,GLP1 inhibitors,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1068020061,1068,H2 receptor antagonist,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1069020061,1069,famotidine,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1070020061,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1071020061,1071,prazosin,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1072020061,1072,terazosin,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1073020061,1073,doxazosin,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1074020061,1074,tamsulosin,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1075020061,1075,BCG vaccine,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1076020061,1076,Colchicine,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1077020061,1077,Losartan,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1078020061,1078,cholecalciferol,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1079020061,1079,Ibrutinib,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1080020061,1080,abiraterone,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1081020061,1081,bicalutamide,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1082020061,1082,emtricitabine,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1083020061,1083,tacrolimus,2006,with  Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
